

### **HEALTH ANNUAL STATEMENT**

FOR THE YEAR ENDED DECEMBER 31, 2023 OF THE CONDITION AND AFFAIRS OF THE

# Arcadian Health Plan, Inc.

NAIC G		0119 NAIC Company Co	de <u>12151</u> Employer's IE	D Number20-1001348	
Organized under the Laws of		(Prior) iington ,	State of Domicile or Port of En	ntry WA	
Country of Domicile		United States	s of America		
Licensed as business type:		Oth	ner		
Is HMO Federally Qualified? Y	es[]No[X]				
Incorporated/Organized	04/06/2004		Commenced Business	01/01/2005	
Statutory Home Office	711 Capitol Way S	S., Suite 204 ,		Olympia, WA, US 98501	
	(Street and N	umber)	(City or	r Town, State, Country and Zip Code)	
Main Administrative Office		500 West M (Street and			
(City or 1	Louisville, KY, US 40202 own, State, Country and Zip			502-580-1000 vrea Code) (Telephone Number)	
Mail Address	P.O. Box 740036			Louisville, KY, US 40201-7436	
Wall / ludi ess	(Street and Number or F			Town, State, Country and Zip Code)	_
Primary Location of Books and	Records		Main Street		
	Louisville, KY, US 40202	(Street and		502-580-1000	
	own, State, Country and Zip	Code)	(A	rea Code) (Telephone Number)	
Internet Website Address		www.hum	ana.com		
Statutory Statement Contact	Lix	z Young (Name)		502-580-3025 (Area Code) (Telephone Number)	
D0	OIINQUIRIES@humana.com (E-mail Address)			502-580-2099 (FAX Number)	—
	(L-mail Address)	OFFIC	EDC	(i Ax Number)	
Chief Executive Officer VP, Associate General	Daniel Andr		Chief Financial Officer	Ashley Nicole Burton #	_
Counsel & Corporate Secretary	Joseph Matthe	ew Ruschell	VP & Treasurer	Robert Martin Marcoux Jr.	
Bruce Dale Brous Courtney Danielle Durall, Ass & Director, Et Catherine Elva Field #, SVP, Matthew George Moorn George Renaudin II, Presid Gilbert Alan Stewart, SVP, N	Medicare Divisional Leader Regional President ent, Medicare & Medicaid	Daniel Kevin Feld # Jeremy Leon Gaskill, VP, M Sean Joseph O'Reilly, SVF Frederick William Roth #,	SVP, Medicaid President  Associate VP, Tax  fedicare Regional President  Chief Compliance Officer  VP, Medicare Supplement  pecialty & Retiree Solutions	Susan Marie Diamond, Executive VP-Finance John-Paul William Felter, SVP, Chief Accounting Offic & Controller John Stephen Littig #, SVP, EG Medical William Mark Preston, VP, Investments Leah Sonnenschein Schraudenbach #, SVP, Chief Ri Officer Ralph Martin Wilson, Vice President	
		DIRECTORS O	R TRUSTEES		
Bruce Dale	Broussard	Joseph Matti	hew Ruschell	Daniel Andrew Tufto #	
State of County of	Kentucky Jefferson	ss s			
all of the herein described assistatement, together with related condition and affairs of the said in accordance with the NAIC A rules or regulations require di respectively. Furthermore, the	ats were the absolute proper exhibits, schedules and expl reporting entity as of the reprinual Statement Instructions ferences in reporting not rescope of this attestation by the differences due to electronication.	by of the said reporting entity, anations therein contained, arorting period stated above, an and Accounting Practices an elated to accounting practice he described officers also inc	free and clear from any liens newed or referred to, is a full at d of its income and deductions d of its income and deductions d so and procedures manual except to so and procedures, according ludes the related correspondinment. The electronic filing may well well well and the country of th	orting entity, and that on the reporting period stated abs or claims thereon, except as herein stated, and that drue statement of all the assets and liabilities and of therefrom for the period ended, and have been comple o the extent that: (1) state law may differ; or, (2) that is to the best of their information, knowledge and be tig electronic filing with the NAIC, when required, that is the requested by various regulators in lieu of or in additional to the results of the requested by a result of the results of the requested by a result of the result of the result of the results of the resu	this f the eted state elief, s an
Subscribed and sworn to before  19th day of  Julia Wentworn  Julia Wentworth  Notary Public  January 10, 2025	Febru JI.	ary, 2024  Jlia Wentworth  Notary Public State at Large  Kentucky	a. Is this an original filing b. If no, 1. State the amendm. 2. Date filed	ent number	

# **ASSETS**

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	1,527,391,867	0	1,527,391,867	1,369,569,043
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	0	0	0	0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$0				
	encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less	0			
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0	0			
	encumbrances)	0	0	0	0
5.	Cash (\$				
	(\$	005 450 050		005 450 050	100 015 500
_	investments (\$21,769,609 , Schedule DA)				
6.	Derivatives (Schedule DB)				
7. g	Other invested assets (Schedule BA)				
8. 9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
	Title plants less \$0 charged off (for Title insurers	, , , ,		, , -,	, , , , , , , , , , , , , , , , , , , ,
	only)	0	0	0	0
14.	Investment income due and accrued				
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	901, 191	449,825	451,367	1,045,878
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$3,381,543 ) and				
	contracts subject to redetermination (\$ 124,504,241 )	127,885,784	0	127,885,784	119,607,010
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies	0	0	0	
17	Amounts receivable relating to uninsured plans				
17. 18.1	Current federal and foreign income tax recoverable and interest thereon				
	Net deferred tax asset				
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software				
21.	Furniture and equipment, including health care delivery assets				
	(\$	32,430	32,430	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0	0
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$ 164,291,208 ) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets	15,244,001	15,244,001	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	2 222 711 210	7/ 075 640	2 150 025 707	1 0/10 760 600
27.	From Separate Accounts, Segregated Accounts and Protected Cell				
۷.	Accounts	0	0	0	0
28.	Total (Lines 26 and 27)	2,233,711,319	74,875,612	2,158,835,707	1,848,763,682
	DETAILS OF WRITE-INS				
1101.		0	0	0	0
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page				0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0		_	0
2501.	Prepaid Commissions				
2502.	Provider Contracts				
2503.	Prepaid Expenses				
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	15,244,001	15,244,001	0	0

# LIABILITIES, CAPITAL AND SURPLUS

	LIADILITIES, CAP				Drior Voor
		1	Current Year	3	Prior Year 4
			-	· ·	·
		Covered	Uncovered	Total	Total
1. C	Claims unpaid (less \$0 reinsurance ceded)	647,008,647	28 , 135 , 482	675, 144, 129	629,451,120
2. A	ccrued medical incentive pool and bonus amounts		0	88,316,039	92,630,827
3. U	Inpaid claims adjustment expenses	3,866,097	0	3,866,097	3,784,664
	ggregate health policy reserves, including the liability of				
	\$0 for medical loss ratio rebate per the Public				
·	Health Service Act	65 000 765	0	65 000 765	27 465 400
	ggregate life policy reserves				
	Property/casualty unearned premium reserves				
7. A	ggregate health claim reserves	0	0	0	0
8. P	Premiums received in advance	5,841,724	0	5,841,724	4,843,146
9. G	Seneral expenses due or accrued	9.123.901	0	9.123.901	12.210.421
	Current federal and foreign income tax payable and interest thereon	., .,.		, ,,,	, ,
	(including \$0 on realized capital gains (losses))	0	0	0	1 613 822
	let deferred tax liability				
	Ceded reinsurance premiums payable				
	mounts withheld or retained for the account of others				
13. R	Remittances and items not allocated	1,309,902	0	1,309,902	4,346,320
14. B	orrowed money (including \$0 current) and				
	interest thereon \$0 (including				
	\$0 current)	0	0	0	0
	*				
	mounts due to parent, subsidiaries and affiliates				
	Perivatives				
17. P	Payable for securities	958,252	0	958,252	124,864
18. P	Payable for securities lending	0	0	0	0
	unds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)	0	0	0	0
					0
	teinsurance in unauthorized and certified (\$0 )				
	companies				0
21. N	let adjustments in assets and liabilities due to foreign exchange rates	0 .	0		0
22. L	iability for amounts held under uninsured plans	227,662,412	0	227,662,412	131,594,010
	ggregate write-ins for other liabilities (including \$				
	current)	1/11 701	0	441 701	106 173
	otal liabilities (Lines 1 to 23)				
	ggregate write-ins for special surplus funds				
	Common capital stock				
27. P	Preferred capital stock	XXX	XXX	0	0
	Gross paid in and contributed surplus				
	Surplus notes				
	ggregate write-ins for other than special surplus funds				
	Jnassigned funds (surplus)	XXX	XXX	454,550,901	304,661,082
32. L	ess treasury stock, at cost:				
3	2.10 shares common (value included in Line 26				
	\$	XXX	XXX	0	0
3:	2.20 shares preferred (value included in Line 27				
	\$ 0 )	XXX	XXX	0	n
22 -	otal capital and surplus (Lines 25 to 31 minus Line 32)				
	otal liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	2,158,835,707	1,848,763,682
	DETAILS OF WRITE-INS				
2301. U	nclaimed Property	441,791	0	441,791	406,473
2302					
	Summary of remaining write-ins for Line 23 from overflow page				
		441,791	0	441,791	
	otals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	,			406,473
2502		XXX	XXX		
2503		XXX	XXX		
2598. S	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
	otals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
				-	
3003		xxx	xxx		
3098. S	Summary of remaining write-ins for Line 30 from overflow page	xxx	xxx	0	0
	otals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0
0000. I	otatio (Enrico odo i tina oddo piao oddo)(Elite od above)	///A	/VV\	U	U

# STATEMENT OF REVENUE AND EXPENSES

		Curren	t Year	Prior Year
		1	2	3
		Uncovered	Total	Total
1.	Member Months	XXX	6,034,366	5,700,931
	Not assessing in a second (including 0	VAVA	7 704 057 401	C 000 440 EEE
2.	Net premium income ( including \$			
3.	Change in unearned premium reserves and reserve for rate credits			
4.	Fee-for-service (net of \$0 medical expenses)			
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues			
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	7,734,857,401	6,823,448,555
	Hospital and Medical:			
9.	Hospital/medical benefits			
10.	Other professional services			
11.	Outside referrals	0	0	0
12.	Emergency room and out-of-area	7,195,781	162,293,121	137,547,972
13.	Prescription drugs	16,470,532	371,475,239	320,087,246
14.	Aggregate write-ins for other hospital and medical	0	0	0
15.	Incentive pool, withhold adjustments and bonus amounts	0	73,044,966	93,042,153
16.	Subtotal (Lines 9 to 15)	287,273,963	6,552,201,545	5,773,942,703
	Less:	, ,	, , ,	, , ,
17.	Net reinsurance recoveries	0	0	0
18.	Total hospital and medical (Lines 16 minus 17)	287,273,963	6,552,201,545	5,773,942,703
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$370,025,919 cost containment expenses			
21.	General administrative expenses			
	·			
22.	Increase in reserves for life and accident and health contracts (including \$0		47 004 704	
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)			
24.	Net underwriting gain or (loss) (Lines 8 minus 23)			
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26.	Net realized capital gains (losses) less capital gains tax of \$(977,564)	0	(6,850,856)	(5,075,596)
27.	Net investment gains (losses) (Lines 25 plus 26)	0	73,686,848	42,897,943
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$0 ) (amount charged off \$0 )]	0	0	0
29.	Aggregate write-ins for other income or expenses	0	77	62
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus			
	27 plus 28 plus 29)			269,047,883
31.	Federal and foreign income taxes incurred	XXX	51,600,812	56,715,212
32.	Net income (loss) (Lines 30 minus 31)	XXX	138,846,614	212,332,671
	DETAILS OF WRITE-INS			
0601.		xxx	0	0
0602.		xxx		
0603		xxx		
0698.	Summary of remaining write-ins for Line 6 from overflow page	xxx	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.		XXX	0	0
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	xxx	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.		0	0	0
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Miscellaneous Income	0	77	62
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	77	62

**STATEMENT OF REVENUE AND EXPENSES (Continued)** 

1	STATEMENT OF REVENUE AND EXPENSES	Oontinaca	/
		Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	930, 291, 835	912 923 407
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets	(4,808,230)	3, 127, 236
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders		(188,000,000
47.	Aggregate write-ins for gains or (losses) in surplus		0
48.	Net change in capital and surplus (Lines 34 to 47)		17,368,427
49.	Capital and surplus end of reporting period (Line 33 plus 48)	1,080,181,654	930,291,835
73.		1,000,101,004	000,201,000
4704	DETAILS OF WRITE-INS		•
4701.			0
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

# **CASH FLOW**

	37 (SITT 25 W		
		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	7,739,617,003	6,848,342,854
2.	Net investment income	82,306,265	44,716,416
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	7,821,923,268	6,893,059,270
5.	Benefit and loss related payments	6,574,241,827	5,762,263,262
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7.	Commissions, expenses paid and aggregate write-ins for deductions	943,984,176	689, 163,323
8.	Dividends paid to policyholders	0	0
9.	Federal and foreign income taxes paid (recovered) net of \$(3,007,720) tax on capital gains (losses)	55,761,548	56,602,758
10.	Total (Lines 5 through 9)	7,573,987,551	6,508,029,343
11.	Net cash from operations (Line 4 minus Line 10)	247,935,718	385,029,927
10	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:  12.1 Bonds	400 570 700	200 052 520
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		124,565
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	410,406,774	310,080,594
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	574,937,804	435,438,733
	13.2 Stocks		0
	13.3 Mortgage loans	0	0
	13.4 Real estate		0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	0	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	574,937,804	435,438,733
14.	Net increase/(decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(164,531,030)	(125,358,140)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	0
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		(33,478,360)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		(221,478,360)
	DECONCILIATION OF CASH CASH EQUIVALENTS AND SHOOT TEDM INVESTMENTS		
18.	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS  Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	102 , 138 , 327	38, 193, 427
19.	Cash, cash equivalents and short-term investments:	102,100,021	00, 100, 121
13.	19.1 Beginning of year	183 315 506	145,122,099
		285,453,853	183,315,526
	19.2 End of year (Line 18 plus Line 19.1)	200,400,000	100,010,020

Note: Supplemental disclosures of cash flow information for non-cash transactions:	

# **ANALYSIS OF OPERATIONS BY LINES OF BUSINESS**

		1		hensive	4	5	6	7	8	9	10	11	12	13	
			(Hospital	& Medical)		_	1	,		Ŭ	10	'''	'-		14
			2	3				Federal							
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Net premium income	7,734,857,401	0	0	0		00	0	7,734,857,401	0	0	0	0	0	0
2.	Change in unearned premium reserves and reserve for rate credit	0	0	0	0		0	0	0	0	0	0	0	0	0
3.	Fee-for-service (net of \$0														
	medical expenses)	0	0	0	0		00	0	0	0	0	0	0	0	XXX
	Risk revenue	0	0	0	0		U	0	0	0	0	0	0	0	XXX
	Aggregate write-ins for other health care related revenues	0	0	0	0		0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	xxx			xxx	XXX	XXX	xxx	XXX	xxx	0
7.	Total revenues (Lines 1 to 6)	7,734,857,401	0	0	0		00	0	7,734,857,401	0	0	0	0	0	0
8.	Hospital/medical benefits	5,801,150,852	0	0	0		0	0	5,801,150,852	0	0	0	0	0	XXX
9.	Other professional services	144,237,366	0	0	0	(	0	0	144,237,366	0	0	0	0	0	XXX
10.	Outside referrals	0	0	0	0		0	0	0	0	0	0	0	0	XXX
11.	Emergency room and out-of-area	162,293,121	0	0	0		0	0	162,293,121	0	0	0	0	0	XXX
12.	Prescription drugs	371,475,239	0	0	0		0	0	371,475,239	0	0	0	0	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0		0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	73,044,966	0	0	0		0	0	73,044,966	0	0	0	0	0	XXX
15.	Subtotal (Lines 8 to 14)	6,552,201,545		l0	0		0	0	6,552,201,545	0	0	0	0	0	XXX
	Net reinsurance recoveries	0	0	0	0	(	0	0	0	0	0	0	0	0	XXX
	Total medical and hospital (Lines 15 minus 16)	6,552,201,545	0	0	0		0	0	6,552,201,545	0	0	0	0	0	XXX
	Non-health claims (net)	0		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
	Claims adjustment expenses including									700			700	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
:	\$370,025,919 cost containment expenses	397,793,179		0	0		00	0	397,793,179	0	0	0	0	0	0
	General administrative expenses	650,800,476	0	0	0		0  0	0	650,800,476	0	0	0	0	0	0
	Increase in reserves for accident and health contracts	17,301,701		0	0		0	0	0	17,301,701	0	0	0	0	XXX
	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)	7,618,096,900	0	0	0		00	0	7,600,795,200	17,301,701	0	0	0	0	0
24.	Net underwriting gain or (loss) (Line 7 minus Line 23)	116,760,501	0	0	0		0 0	0	134,062,202	(17,301,701)	0	0	0	0	0
	DETAILS OF WRITE-INS														2007
0501.															XXX
0502.															XXX
0503. 0598.	Summary of remaining write-ins for Line 5 from														XXX
0599.	overflow page												0		
205:	above)	0		0	0	1	0	0	0	0	0	0	v	0	XXX
0601.		0		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	xxx	xxx	xxx	xxx	XXX	XXX	xxx	xxx	xxx	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	xxx	xxx	XXX	XXX	XXX	XXX	XXX	XXX	XXX	xxx	XXX	0
1301.															XXX
1302.													.		XXX
1303.															XXX
	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	n	(	) n	0	0	0	0	0	0		XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	n		0	0	0	0	Λ	0	0	0	XXX

\_

#### \_\_

#### ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Arcadian Health Plan Inc.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 1 - PREMILIMS

PART 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical) individual	0	0	0	0
Comprehensive (hospital and medical) group	0	0	0	0
3. Medicare Supplement	0	0	0	0
4. Vision only	0	0	0	0
5. Dental only	0	0	0	0
6. Federal Employees Health Benefits Plan	0	0	0	0
7. Title XVIII - Medicare	7,734,857,401	0	0	7,734,857,401
8. Title XIX - Medicaid	0	0	0	0
9. Credit A&H	0	0	0	0
10. Disability Income	0	0	0	0
11. Long-Term Care	0	0	0	0
12. Other health	0	0	0	0
13. Health subtotal (Lines 1 through 12)	7,734,857,401	0	0	7,734,857,401
14. Life	0	0	0	0
15. Property/casualty	0	0	0	0
16. Totals (Lines 13 to 15)	7,734,857,401	0	0	7,734,857,401

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:														
	1.1 Direct	6,496,453,830	0	0	0	0	0	0	6,496,453,830	0	0	0	0	0	0
	1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.4 Net	6,496,453,830	0	0	0	0	0	0	6,496,453,830	0	0	0	0	0	0
2.	Paid medical incentive pools and bonuses	77,359,754	0	0	0	0	0	0	77,359,754	0	0	0	0	0	0
	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	675 , 144 , 129	0	0	0	0	0	0		0	0	0	0	0	0
	3.2 Reinsurance assumed	0	0  .	0	0	J0	J0	J0	0	J0	0	0	0	0	0
	3.3 Reinsurance ceded	0	0	0	0	0	0	J0	0	J0	0	0	0	0	0
	3.4 Net	675 , 144 , 129	0	0	0	0	0	0	675 , 144 , 129	0	0	0	0	0	0
	4.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Accrued medical incentive pools and bonuses, current year	88,316,039	0	0	0	0	0	0	88,316,039	0	0	0	0	0	0
6.	Net health care receivables (a)	62,990,260	0	0	0	0	0	0	62,990,260	0	0	0	0	0	0
7.	Amounts recoverable from reinsurers December 31, current year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Claim liability December 31, prior year from Part 2A:	000 454 400							000 454 400						
	8.1 Direct	629,451,120	0	0	0	0	0	0		0	0	0	0	0	0
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	8.4 Net	629,451,120	0	0	0	0	0	0	629,451,120	0	0	0	0	0	0
	from Part 2D:	_	_ [	-		_		_	_	_	_	_		_	_
	9.1 Direct	0	0	0	0	J0	0	ļ0	ļ0	J0	0	0	0	0	0
	9.2 Reinsurance assumed	0	<u>0</u>  .	0	0	0	0	J0	0	J0	0	0	0	0	ļ0
	9.3 Reinsurance ceded	0	0  .	0	0	0	0	J0	0	J0	0	0	0	0	0
	9.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Accrued medical incentive pools and bonuses, prior year	92,630,827	0	0	0	0	0	0	92,630,827	0	0	0	0	0	0
	Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Incurred Benefits: 12.1 Direct	6,479,156,579	0	0	0	0	0	0	6,479,156,579	0	0	0	0	0	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	12.4 Net	6,479,156,579	0	0	0	0	0	0	6,479,156,579	0	0	0	0	0	0
	Incurred medical incentive pools and bonuses	73,044,966	0	0	0		0	0		0	0	0		0	0

<sup>(</sup>a) Excludes \$ ......0 loans or advances to providers not yet expensed.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

		1 4	0					D OF CURREN	I ILAN		40	4.4	10	40	1 44 1
		1	Compre (Hospital &		4	5	6	/	8	9	10	11	12	13	14
			2	3				Federal Employees							
					Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Čare	Other Health	Non-Health
1. R	eported in Process of Adjustment:														
1.	1 Direct	90,704,638	0	0	0	0	0	0	90,704,638	0	0	0	0	0	0
1.	2 Reinsurance assumed	0 .	0		0		0	0			0	0	0	0	0
1.	3 Reinsurance ceded	0 .	0	0	0	0	0	0	0	0	0	0	0	0	0
1.	4 Net	90,704,638	0	0	0	0	0	0	90,704,638	0	0	0	0	0	0
	curred but Unreported:														
2.	1 Direct	460 , 784 , 522			0					0			0	0	0
2.	2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.	3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	.4 Net		0			0							0	0	0
	mounts Withheld from Paid Claims and Capitations:														
3.	1 Direct	123,654,969	0	0	0	0	0	0	123,654,969	0	0	0	0	0	0
3.	2 Reinsurance assumed	0	0				0		0	0		0	0	0	0
3.	3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 Net	123 . 654 . 969	0	0				0		0			0	0	0
4. T	OTALS:														
4.	1 Direct	675 , 144 , 129	0	0	0	0	0	0	675 , 144 , 129	0	0	0	0	0	0
4.	2 Reinsurance assumed	0 .	0	0		0	0	0	0	0		0	0	0	0
4.	3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 Net	675, 144, 129	0	0	0	0	0	0	675, 144, 129	0	0	0	0	0	0

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	Ouring the Year	Claim Reserve a		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	0	0	0	0	0	0
Comprehensive (hospital and medical) group	0	0	0	0	0	0
3. Medicare Supplement	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Dental Only	0	0	0	0	0	0
6. Federal Employees Health Benefits Plan	0	0	0	0	0	0
7. Title XVIII - Medicare		6,124,202,672	37 , 752 , 157	637,391,972	410,003,315	629,451,120
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	0	0	0	0	0	0
13. Health subtotal (Lines 1 to 12)		6,124,202,672	37 , 752 , 157	637,391,972	410,003,315	629,451,120
14. Health care receivables (a)	2,768,891	219,468,077	0	0	2,768,891	159,246,707
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts		0	4,970,654	83,345,385	82,330,408	92,630,827
17. Totals (Lines 13 - 14 + 15 + 16)	446,842,021	5,904,734,595	42,722,811	720,737,357	489,564,832	562,835,240

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

	Cumulative Net Amounts Paid				
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	212,173	210 , 131	209,390	209,150	209, 150
2. 2019	3,332,824	3,690,948	3,684,687	3,684,024	3,683,656
3. 2020	XXX	4,020,354	4,439,437	4,438,798	4,438,985
4. 2021	XXX	XXX	5,071,170	5,536,547	5,539,328
5. 2022	XXX	XXX	XXX	5,298,429	5,745,439
6. 2023	XXX	XXX	XXX	XXX	6,124,203

#### Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net A		Liability, Claim Rese standing at End of Ye		ve Pool and Bonuses
	1 2 3 4				
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	222,912	210,451	209,390	209, 150	209, 150
2. 2019	3,761,293	3,699,037	3,685,658	3,684,024	3,683,656
3. 2020	XXX	4,671,344	4,508,629	4,439,309	4,438,985
4. 2021	XXX	XXX	5,720,472	5,586,150	5,540,003
5. 2022	XXX	XXX	XXX	5,970,396	5,787,487
6. 2023	XXX	XXX	XXX	XXX	6,844,940

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	4,345,828	3,683,656	35,032	1.0	3,718,687	85.6	0	0	3,718,687	85.6
2.	2020		4,438,985	42,215	1.0	4,481,200	81.3	0	0	4,481,200	81.3
3.	2021		5,539,328	52,679	1.0	5,592,007	87.8	674	3	5,592,685	87.8
4.	2022	6,823,449	5,745,439	54,639	1.0	5,800,078	85.0	42,049	213	5,842,339	85.6
5.	2023	7,734,857	6,124,203	58,241	1.0	6,182,444	79.9	720,737	3,650	6,906,831	89.3

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XIX

Cumulative Net Amounts Paid			Paid		
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior					
2. 2019					
3. 2020	XXX				
4. 2021	XXX	XXX			
5. 2022	XXX	XXX	XXX		
6. 2023	XXX	XXX	XXX	XXX	

#### Section B - Incurred Health Claims - Title XIX

Godion B internet realing that Alex							
	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool Outstanding at End of Year						
	1 2 3 4						
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1. Prior							
2. 2019							
3. 2020	XXX						
4 2021	XXX	XXX					
5. 2022	XXX	XXX	XXX				
6. 2023	XXX	XXX	XXX	XXX			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
were Incurred	Premiums Earned	Claims Payment	ense ymer	Perc		Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1. 2019				,						
2 2020										
3 2021										
0. 2021					·····					
4. 2022										
5. 2023										

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid				
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. F	Prior	212, 173	210 , 131	209,390	209, 150	209, 150
2. 2	2019	3,332,824	3,690,948	3,684,687	3,684,024	3,683,656
3. 2	2020	XXX	4,020,354	4,439,437	4,438,798	4,438,985
4. 2	2021	XXX	XXX	5,071,170	5,536,547	5,539,328
5. 2	2022	XXX	XXX	XXX	5,298,429	5,745,439
6. 2	2023	XXX	XXX	XXX	XXX	6,124,203

#### Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	mount Paid and Claim	Liability, Claim Rese standing at End of Yea	rve and Medical Incenti ar	ve Pool and Bonuses
	1 2 3 4				
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	222,912	210,451	209,390	209, 150	209, 150
2. 2019	3,761,293	3,699,037	3,685,658	3,684,024	3,683,656
3. 2020	XXX	4,671,344	4,508,629	4,439,309	4,438,985
4. 2021	XXX	XXX	5,720,472	5,586,150	5,540,003
5. 2022	XXX	XXX	XXX	5,970,396	5,787,487
6. 2023	XXX	XXX	XXX	XXX	6,844,940

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	4,345,828	3,683,656	35,032	1.0	3,718,687	85.6	0	0	3,718,687	85.6
2.	2020	5,513,802	4,438,985	42,215	1.0	4,481,200	81.3	0	0	4,481,200	81.3
3.	2021	6,368,144	5,539,328	52,679	1.0	5,592,007	87.8	674	3	5,592,685	87.8
4.	2022	6.823.449	5.745.439	54 .639	1.0	5.800.078	85.0	42.049	213	5.842.339	85.6
5.	2023	7,734,857	6,124,203	58,241	1.0	6,182,444	79.9	720,737	3,650	6,906,831	89.3

# **UNDERWRITING AND INVESTMENT EXHIBIT**

	PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY													
		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13
			2 (HOSPITAL &	3	_			Federal						
					Medicare			Employees Health	T:41- \0 (III	Title XIX		Disability.	T	
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Title XVIII Medicare	Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
2.	Additional policy reserves (a)	17,301,701	0	0	0	0	0	0	0	17,301,701	0	0	0	0
3.	Reserve for future contingent benefits	0		0	0	0	0	0	0	0	0	0	0	0
4.	Reserve for rate credits or experience rating refunds													
	(including \$0 for investment income)	10,912,362	0	0	0	0	0	0	10,912,362	0	0	0	0	0
5.	Aggregate write-ins for other policy reserves	37,775,702	0	0	0	0	0	0	37,775,702	0	0	0	0	0
6.	Totals (gross)	65,989,765	0	0	0	0	0	0	48,688,064	17,301,701	0	0	0	0
7.	Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	65,989,765	0	0	0	0	0	0	48,688,064	17,301,701	0	0	0	0
9.	Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	Risk Adjustment Premium Payable	37,775,702	0	0	0	0	0	0	37,775,702	0	0	0	0	0
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	37,775,702	0	0	0	0	0	0	37,775,702	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ ......17,301,701 premium deficiency reserve.

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 3 - ANALYSIS OF EXPENSES

1	ljustment Expenses 2	3	4	5
Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
y of				
636	,083 159,705	2,402,034	3,973	3,201,79
55,046	,069 12,834,978	216,729,879	354,436	284,965,36
ned)	0	179,009,808	4, 198	179,014,00
1,041	,671261,537	4,104,868	6,625	5,414,70
15,	,890 12,261	187,986	309	216,4
	,574383,606	5,279,320	8,476	7,196,9
620	,444155,778	2,246,316	3,664	3,026,2
9,832,			61,034	49,154,6
4,056		15,601,338	25,451	20,701,0
	,984			2.809.4
668				3,440,9
36				, ,
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,
9,656	,7062,424,775		18,047	48,973,2
nd 275 152	,2014,916,818	103 902 912	164 755	384 136 6
	,815			
	,83196,620			
581		2,243,518		
	,284		•	
	0			
	0			
	,329207,970			
	0	0	0	
		, , , , ,		
		0		
	0			
	0	12,352,711	20 , 174	12,372,8
	0	931,593	255	931,8
	,847 445,867			
	,554 13,449		134	2,451,1
	,919 27,767,260		1.412.747	
/ear				12,989,9
·	, ,	12,210,421		, ,
5,				
5,	0 0	1,422,455	0	1,422,4
370,025	,919 27,685,827	643,228,444	1,412,747	1,042,352,9
53	,554	2,384,044	134	2,451,1
m		0	0	
25				2,451,1
25	53,	53,554 13,449		53,554 13,449 2,384,044 134

# **EXHIBIT OF NET INVESTMENT INCOME**

		1	2
		Collected During Year	
1.	U.S. government bonds		4, 184, 249
1.1	Bonds exempt from U.S. tax	(a)0	0
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates		
2.1	Preferred stocks (unaffiliated)	(b) 0	0
2.11	Preferred stocks of affiliates	(b) 0	0
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans		
4.	Real estate	(d)0	0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)32, 103, 198	31,975,225
7	Derivative instruments	(f)0	0
8.	Other invested assets		
9.	Aggregate write-ins for investment income	0	7,464
10.	Total gross investment income	80,203,571	81,950,451
11.	Investment expenses		(g)1,388,472
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)24,275
13.	Interest expense		(h)0
14.	Depreciation on real estate and other invested assets		(i)0
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		1,412,747
17.	Net investment income (Line 10 minus Line 16)		80,537,704
	DETAILS OF WRITE-INS		
0901.	Miscellaneous Investment Income	0	7,464
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	7,464
1501.			0
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
	des \$		
	des \$ 0 accrual of discount less \$ 0 amortization of premium and less \$	•	·
(c) Inclu	des \$ 0 accrual of discount less \$ 0 amortization of premium and less \$	. 0 paid for accrued int	erest on purchases.

**EXHIBIT OF CAPITAL GAINS (LOSSES)** 

(d) Includes \$ .......0 for company's occupancy of its own buildings; and excludes \$ .......0 interest on encumbrances.

(f) Includes \$ ...... 0 accrual of discount less \$ ...... 0 amortization of premium.

(g) Includes \$.

segregated and Separate Accounts.

	EVUIDIT	OF CAPI	IAL GAIN	3 (LUSSE	.S)	
		1	2	3	4	5
				Total Realized Capital		Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity		(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	1,082,151	0	1,082,151	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	(8,911,227)	0	(8,911,227)	3,853,282	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates			0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans			0	0	
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	
6.	Cash, cash equivalents and short-term investments	656	0	656	0	C
7.	Derivative instruments	0	0	0	0	
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(7,828,420)		(7,828,420)	3,853,282	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	C
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	C

# **EXHIBIT OF NON-ADMITTED ASSETS**

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	0	0	0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens	0	0	0
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
••	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
		0		0
15.	Premiums and considerations:	440 005	670 507	222 702
	15.1 Uncollected premiums and agents' balances in the course of collection			
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
	Amounts receivable relating to uninsured plans			33,734
	Current federal and foreign income tax recoverable and interest thereon		0	0
18.2	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates	0	0	0
24.	Health care and other amounts receivable	57,945,759	29,911,171	(28,034,588
25.	Aggregate write-ins for other than invested assets	15,244,001	37,936,991	22,692,990
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28.	Total (Lines 26 and 27)	74,875,612	70,067,382	(4,808,230
1101.	DETAILS OF WRITE-INS	0	0	0
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page			
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Commissions			
2501. 2502.	Provider Contracts		6,750,748	
2502. 2503.	Prepaid Expenses			
∠ນ∪პ.	Summary of remaining write-ins for Line 25 from overflow page		0	
2598.			. ()	

# 17

# **EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY**

			Total Members at End of			6	
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months	
Source of Enformment	FIIOI Teal	First Quarter	Second Quarter	Tilliu Quartei	Current real	Member Months	
Health Maintenance Organizations	456,254	430, 114	435 , 435	441,249	439,924	5,218,667	
Provider Service Organizations	0	0	0	0	0	0	
Preferred Provider Organizations	15,207	5,900	6,877	7,783	7,970	82,330	
4. Point of Service	0	60,095	60,978	62,060	62,922	733,369	
5. Indemnity Only	0	0	0	0	0	0	
Aggregate write-ins for other lines of business.	. 0	0	0	0	0	0	
7. Total	471,461	496,109	503,290	511,092	510,816	6,034,366	
DETAILS OF WRITE-INS							
0601.							
0602.							
0603.							
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0	

#### NOTES TO THE FINANCIAL STATEMENTS

#### 1. <u>Summary of Significant Accounting Policies and Going Concern</u>

#### A. Accounting Practices

The financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the Washington Office of Insurance.

The Washington Office of Insurance (the Office) recognizes only statutory accounting practices prescribed or permitted by the State of Washington for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Washington Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual (NAIC SSAP) has been adopted as a component of prescribed or permitted practices by the State of Washington. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices. No deviations from the Codification currently exist.

A reconciliation of the Company's net income and capital and surplus between NAIC SSAP and practices prescribed and permitted by the State of Washington is shown below:

	SSAP#	F/S Page	F/S Line #		2023	_	2022
Net Income				-			_
<ol> <li>Arcadian Health Plan, Inc.</li> </ol>	XXX	XXX	XXX	\$	138,846,614	\$	212,332,671
Washington basis							
2. State Prescribed Practices that is							
an increase/(decrease) NAIC					-		-
SSAP							
3. State Permitted Practices that is an							
increase/(decrease) NAIC SSAP					-		
4. NAIC SSAP	XXX	XXX	XXX	\$ .	138,846,614	\$	212,332,671
Complete							
Surplus				Ф	1 000 101 654	ф	020 201 025
<ol><li>Arcadian Health Plan, Inc. Washington basis</li></ol>	XXX	XXX	XXX	\$	1,080,181,654	\$	930,291,835
6. State Prescribed Practices that is							
an increase/(decrease) NAIC					-		-
SSAP							
7. State Permitted Practices that is an increase/(decrease) NAIC SSAP					_		_
8. NAIC SSAP	XXX	XXX	XXX	\$	1,080,181,654	\$	930,291,835

#### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results could differ from those estimates.

#### C. Accounting Policy

Premiums are reported as earned in the period in which members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. Premiums received prior to such period are recorded as advance premiums.

Benefits incurred and loss adjustment expenses include claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses, legal and administrative costs to settle claims, and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care provided prior to the date of the statements of admitted assets, liabilities and surplus. Capitation payments represent monthly contractual fees disbursed to participating primary care physicians, and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments mainly in U.S. Government obligations with a maturity of twelve months or less from the date of purchase. Short-term investments are recorded at amortized cost. The carrying value of short-term investments approximates fair value due to the short-term maturities of the investments.
- (2-4) Investments are valued and classified in accordance with methods prescribed by the NAIC. Bonds with an NAIC rating of 1 or 2 are carried at amortized cost, with all other bonds being recorded at the lower of amortized cost or fair value; redeemable preferred stocks are carried at amortized cost; and non-redeemable preferred stocks are carried at fair value.

The Company regularly evaluates investment securities for impairment. For all securities other than loan-backed and structured securities, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value, the near term prospects for recovery to carrying value, and the Company's intent and ability to hold the investment until maturity or market recovery is realized. If and when a determination is made that a decline in fair value below the cost basis is other-than-temporary, the related investment is written down to its estimated fair value through earnings.

Amortization of bond premium or discount is computed using the scientific interest method.

Income from investments is recorded on an accrual basis. For the purpose of determining realized gains and losses, the cost of securities sold is based upon specific identification. Investment income due and accrued over 90 days past due is nonadmitted.

#### NOTES TO THE FINANCIAL STATEMENTS

- (5) Not Applicable.
- For loan backed and structured securities where the securities fair value is less than the amortized cost, the Company considers several factors to determine if the security's impairment is other-than-temporary. If the Company has the intent to sell the security or if the Company does not have the intent and ability to retain the security until recovery of its fair value, the related investment is written down to its estimated fair value through earnings. If, however, the Company has the intent and ability to retain the security until recovery of its fair value, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value and the near term prospects for recovery to carrying value. If the determination is made, based on these factors, that the Company does expect to recover the entire amortized cost of the security, then an other-than-temporary impairment has not occurred. If, however, the determination is made that the Company does not expect to recover the entire amortized cost of the security based on the factors noted above, the Company recognizes a realized loss in earnings for the non-interest related decline. No loss is recognized for the interest impairment.
- (7) Not Applicable.
- (8) Not Applicable.
- (9) Not Applicable.
- (10-11) The estimates of future medical benefit payments are developed using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical development such as claim inventory levels and claim receipt patterns, and other relevant factors. Corresponding administrative costs to process outstanding claims are estimated and accrued. Estimates of future payments relating to services incurred in the current and prior periods are continually reviewed by management and adjusted as necessary.

The Company assesses the profitability of its contracts for providing health insurance coverage to its members when current operating results or forecasts indicate probable future losses. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses and maintenance costs exceed related future premiums. Investment income is not contemplated in the calculation of the premium deficiency liability.

Management believes the Company's benefits payable and loss adjustment expense are adequate to cover future claims and loss adjustment expense payments required, however, such estimates are based on knowledge of current events and anticipated future events and, therefore, the actual liability could differ from the amounts provided.

(12) The Company has not modified its capitalization policy from the prior period.

Equipment is stated at cost less accumulated depreciation. Depreciation expense is computed using the straightline method over estimated useful lives generally ranging from three to five years. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.

The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements. The temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled.

- (13) The Company estimates anticipated Pharmacy Rebate Receivables using the analysis of historical recovery patterns.
- (14) Not Applicable.
- (15) Not Applicable.
- D. Going Concern

Management of the Company has evaluated the Company's ability to continue as a going concern under SSAP No. 1, *Accounting Policies, Risks & Uncertainties, and Other Disclosures* (SSAP No. 1). Based on this evaluation, Management has determined that there is no substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

Not Applicable.

- 3. <u>Business Combinations and Goodwill</u>
  - A. Statutory Purchase Method

Not Applicable.

B. Statutory Merger

Not Applicable.

C. Assumption Reinsurance

Not Applicable.

D. Impairment Loss

#### NOTES TO THE FINANCIAL STATEMENTS

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill Not Applicable.

4. <u>Discontinued Operations</u>

Not Applicable.

- 5. Investments
  - A. Mortgage Loans, Including Mezzanine Real Estate Loans

Not Applicable.

B. Debt Restructuring

Not Applicable.

C. Reverse Mortgages

Not Applicable.

- D. Loan-Backed Securities
  - Prepayment assumptions for mortgage-backed/loan-backed and structured securities were obtained from industry market sources.
  - (2) Not Applicable.
  - (3) Not Applicable.
  - (4) The Company does not have any investments in an other-than-temporary impairment position at December 31, 2023.

Gross unrealized losses and related fair value of temporarily impaired securities that have been in a continuous unrealized loss position were as follows at December 31, 2023:

(a) The aggregate amount of unrealized losses:

 1. Less than Twelve Months
 \$ (1,525,704)

 2. Twelve Months or Longer
 \$ (51,512,968)

(b) The aggregate related fair value of securities with unrealized losses:

 1. Less than Twelve Months
 \$ 104,248,482

 2. Twelve Months or Longer
 \$ 421,741,608

- (5) Unrealized losses are primarily due to increases in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. All issuers of securities trading at an unrealized loss remain current on all contractual payments and the Company believes it is probable that all amounts due according to the contractual terms of the debt securities are collectible. After taking into account these and other factors, including the severity of the decline and the Company's ability and intent to hold these securities until recovery or maturity, the Company determined the unrealized losses on these investment securities were temporary and, as such, no impairment was required.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions
  - (1) The Company has no repurchase agreements or securities lending transactions.
  - (2) The Company has not pledged any of its assets as collateral.
  - (3-7) Not Applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

H. Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

J. Real Estate

#### NOTES TO THE FINANCIAL STATEMENTS

K. Low-Income Housing Tax Credits (LIHTC)

Not Applicable.

#### L. Restricted Assets

(1) Restricted Assets (Including Pledged)

	1 Total Gross	2 Total Gross	3	4	5	Percentage Gross (Admitted &	7 Percentage Admitted
	(Admitted & Nonadmitted) Restricted from	(Admitted & Nonadmitted) Restricted from	Increase/ (Decrease)	Total Current Year Nonadmitted	Total Current Year Admitted Restricted	Nonadmitted) Restricted to Total Assets	Restricted to Total Admitted
Restricted Asset Category	Current Year	Prior Year	(1 minus 2)	Restricted	(1 minus 4)	(a)	Assets (b)
a. Subject to contractual							
obligation for which	Φ.		Φ.		Φ.	0.4	2/
liability is not shown	\$ -	\$ -	\$ -	\$ -	\$ -	-%	-%
b. Collateral held under							
security lending agreements							
c. Subject to repurchase	-	-	-	-	-	-	-
agreements	_	_	_		_	_	_
d. Subject to reverse							
repurchase agreements	_	_	_	_	_	_	_
e. Subject to dollar							
repurchase agreements	-	-	-	-	-	-	-
f. Subject to dollar reverse							
repurchase agreements	-	-	-	-	-	-	-
g. Placed under option							
contracts	-	-	-	-	-	-	-
h. Letter stock or securities							
restricted to sale –							
excluding FHLB capital stock							
i. FHLB capital	-	-	-	-	-	-	-
stock	_	_	_	_	_	_	_
j. On deposit with states	12,011,049	12,041,820	(30,771)	_	12,011,049	0.54%	0.56%
k. On deposit with other	,- ,	,- ,	(,,		,, ,, ,,		
regulatory bodies	-	-	-	-	-	-	-
<ol> <li>Pledged collateral to</li> </ol>							
FHLB (including							
assets backing funding							
agreements)	-	-	-	-	-	-	-
m. Pledged as collateral not							
captured in other categories							
n. Other restricted assets	-	-	-	-	-	-	-
o. Total Restricted Assets	\$ 12,011,049	\$ 12,041,820	\$ (30,771)		\$ 12,011,049	0.54%	0.56%
o. Total Restricted / 1880ts	Ψ 12,011,047	Ψ 12,071,020	ψ (30,771)		Ψ 12,011,07)	U.J-T/U	0.5070

6

(2) Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(3) Detail of Other Restricted Assets Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not Applicable.

M. Working Capital Finance Investments

Not Applicable.

N. Offsetting and Netting of Assets and Liabilities

Not Applicable.

O. 5GI\* Securities

Not Applicable.

P. Short Sales

Not Applicable.

Q. Prepayment Penalty and Acceleration Fees

#### **NOTES TO THE FINANCIAL STATEMENTS**

R. Share of Cash Pool by Asset Type

Not Applicable.

#### 6. <u>Joint Ventures, Partnerships and Limited Liability Companies</u>

- A. The Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10.0 percent of its admitted assets.
- B. The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships and Limited Liability Companies during the statement periods.

#### 7. <u>Investment Income</u>

A. Due and accrued income was excluded from surplus on the following basis:

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.

- B. The total amount excluded was \$0.
- C. The gross, nonadmitted and admitted amounts for interest income due and accrued.

Intere	st Income Due and Accrued	Amount
1.	Gross	\$ 10,788,918
2.	Nonadmitted	\$ -
3.	Admitted	\$ 10,788,918

D. The aggregate deferred interest.

Amount

Aggregate Deferred Interest \$

E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance.

Amount

Cumulative amounts of PIK interest included in the current principal balance \$

8. <u>Derivative Instruments</u>

Not Applicable.

#### 9. <u>Income Taxes</u>

The Inflation Reduction Act (Act) was enacted on August 16, 2022 and included a new corporate alternative minimum tax (CAMT). The Act and the CAMT went into effect for tax years beginning after 2022. The Company is an applicable corporation for 2023 as the average adjusted financial statement income for Humana Inc. and Subsidiaries for the applicable three-tax-year period exceeds the \$1 billion income-based threshold. However, the Company does not expect to incur a CAMT liability in 2023 as its regular tax liability is expected to exceed the tentative minimum tax. Further, no other taxable entities or taxable groups within the Company's structure are expected to exceed the average adjusted financial statement income threshold. The Company has not made an accounting policy election to disregard CAMT when evaluating the need for a valuation allowance for its non-CAMT DTAs.

#### A. Deferred Tax Assets/(Liabilities)

(1) The components of the net admitted deferred tax asset/(liability) by tax character were as follows:

		December 31, 2023					
			Ordinary		Capital		Total
a.	Gross deferred tax assets	\$	29,207,634	\$	1,082,693	\$	30,290,327
b.	Statutory valuation allowance adjustments		-		(1,082,693)		(1,082,693)
c.	Adjusted gross deferred tax assets		29,207,634		-		29,207,634
d.	Deferred tax assets nonadmitted		(278,133)		-		(278,133)
e.	Net admitted deferred tax assets		28,929,501		-		28,929,501
f.	Deferred tax liabilities		(22,116)		-		(22,116)
g.	Net admitted deferred tax asset/(liability)	\$	28,907,385	\$	-	\$	28,907,385
			_				
				Dece	mber 31, 2022		
			Ordinary		Capital		Total
a.	Gross deferred tax assets	\$		\$		\$	Total 19,110,756
a. b.	Gross deferred tax assets Statutory valuation allowance adjustments	\$	Ordinary		Capital		
		\$	Ordinary		Capital 1,891,882		19,110,756
b.	Statutory valuation allowance adjustments	\$	Ordinary 17,218,874		Capital 1,891,882		19,110,756 (1,891,882)
b. с.	Statutory valuation allowance adjustments Adjusted gross deferred tax assets	\$	Ordinary 17,218,874 - 17,218,874		Capital 1,891,882		19,110,756 (1,891,882) 17,218,874
b. c. d.	Statutory valuation allowance adjustments Adjusted gross deferred tax assets Deferred tax assets nonadmitted	\$	Ordinary 17,218,874 - 17,218,874 (587,494)		Capital 1,891,882		19,110,756 (1,891,882) 17,218,874 (587,494)

#### NOTES TO THE FINANCIAL STATEMENTS

		Change					
			Ordinary		Capital		Total
a.	Gross deferred tax assets	\$	11,988,760	\$	(809,189)	\$	11,179,571
b.	Statutory valuation allowance adjustments		-		809,189		809,189
c.	Adjusted gross deferred tax assets		11,988,760		-		11,988,760
d.	Deferred tax assets nonadmitted		309,361		-		309,361
e.	Net admitted deferred tax assets		12,298,121		-		12,298,121
f.	Deferred tax liabilities		9,393		-		9,393
g.	Net admitted deferred tax asset/(liability)	\$	12,307,514	\$	-	\$	12,307,514

(2) The amount of admitted adjusted gross deferred tax assets under SSAP No. 101 were as follows:

		Dec	ember 31, 202	3	
	Ordinary		Capital		Total
<ul> <li>a. Federal income taxes paid in prior years recoverable through loss carrybacks</li> <li>b. Adjusted gross deferred tax assets expected</li> </ul>	\$ 28,791,788	\$	-	\$	28,791,788
to be realized after application of the threshold limitation  1. Adjusted gross deferred tax assets expected to be realized following the Balance Sheet	115,597		-		115,597
date	XXX		XXX		115,597
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX		XXX		157,691,140
c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities	 22,116		-		22,116
d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 28,929,501	\$	-	\$	28,929,501
	 Ordinary	Dec	ember 31, 202 Capital	2	Total
<ul><li>a. Federal income taxes paid in prior years recoverable through loss carrybacks</li><li>b. Adjusted gross deferred tax assets expected</li></ul>	\$ 16,212,016	\$	-	\$	16,212,016
to be realized after application of the threshold limitation  1. Adjusted gross deferred tax assets expected	387,855		-		387,855
to be realized following the Balance Sheet date	XXX		XXX		387,855
Adjusted gross deferred tax assets allowed per limitation threshold	XXX		XXX		137,053,795
c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities	 31,509		-		31,509
d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 16,631,380	\$	-	\$	16,631,380
	 Ordinary		Change Capital		Total
<ul> <li>a. Federal income taxes paid in prior years recoverable through loss carrybacks</li> <li>b. Adjusted gross deferred tax assets expected</li> </ul>	\$ 12,579,772	\$	-	\$	12,579,772
to be realized after application of the threshold limitation  1. Adjusted gross deferred tax assets expected	(272,258)		-		(272,258)
to be realized following the Balance Sheet date	XXX		XXX		(272,258)
Adjusted gross deferred tax assets allowed per limitation threshold  Adjusted gross deferred tax assets affect by	XXX		XXX		20,637,345
c. Adjusted gross deferred tax assets offset by gross deferred tax liabilities	 (9,393)				(9,393)
d. Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 12,298,121	\$		\$	12,298,121

(3) The ratio percentage used to determine recovery period and threshold limitation amount was as follows:

		December 31, 2023	December 31, 2022
a.	Ratio percentage used to determine recovery period		·
	and threshold limitation amount	585%	544%
b.	Amount of adjusted capital and surplus used to		
	determine recovery period and threshold limitation		
	in 2 b.2 above	1,051,274,269	913,691,964

#### NOTES TO THE FINANCIAL STATEMENTS

(4) The impact of tax planning strategies on adjusted gross DTAs and net admitted DTAs was as follows:

		ber 31, 2	
Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a	 Ordinary		Capital
percentage  1. Adjusted gross DTAs amount from note 9A1(c)	\$ 29,207,634	\$	-
<ol> <li>Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies</li> <li>Net admitted adjusted gross DTAs amount from note</li> </ol>	0.00%		0.00%
9A1(e) 4. Percentage of net admitted adjusted gross DTAs by tax	\$ 28,929,501	\$	-
character admitted because of the impact of tax planning strategies	0.00%		0.00%
	Decem Ordinary	iber 31, 2	2022 Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a	•		
percentage 1. Adjusted gross DTAs amount from note 9A1(c) 2. Percentage of adjusted gross DTAs by tax character	\$ 17,218,874	\$	-
attributable to the impact of tax planning strategies 3. Net admitted adjusted gross DTAs amount from note	0.00%		0.00%
<ul><li>9A1(e)</li><li>4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning</li></ul>	\$ 16,631,380	\$	-
strategies	0.00%		0.00%
	Ordinary (	Change	Capital
Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage			
1. Adjusted gross DTAs amount from note 9A1(c)	\$ 11,988,760	\$	-
<ol> <li>Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies</li> <li>Net admitted adjusted gross DTAs amount from note</li> </ol>	0.00%		0.00%
9A1(e)	\$ 12,298,121	\$	-
<ol> <li>Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies</li> </ol>	0.00%		0.00%

- b. Does the Company's tax planning strategies include the use of reinsurance? Yes  $[ \quad ]$  No  $[ \quad X \quad ]$
- B. There are no temporary differences for which a DTL has not been established.
- C. Current and deferred income taxes
  - $(1) \quad \hbox{Current income taxes incurred consist of the following major components:}$

		December 31, 2023	December 31, 2022	Change
a.	Federal	\$ 51,706,957	\$ 56,716,592 \$	(5,009,635)
b.	Foreign			
c.	Subtotal	51,706,957	56,716,592	(5,009,635)
d.	Federal income tax on net capital gains	(977,564)	(1,349,209)	371,645
e.	Utilization of capital loss carryforwards	-	-	-
f.	Other	(106,145)	(1,380)	(104,765)
g.	Federal and foreign income taxes incurred	\$ 50,623,248	\$ 55,366,003 \$	(4,742,755)

### NOTES TO THE FINANCIAL STATEMENTS

(2–3) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

DTAs resulting from Book/Tax Differences in:

a.	Ordinary		December 31, 2023	December 31, 2022	Change
	Discounting of unpaid losses	\$	13,838,171	\$ 7,557,304	\$ 6,280,867
	2. Unearned premium reserve		245,353	203,412	
	3. Policyholder reserves		-	-	-
	4. Investments and other		_	_	_
	5. Deferred acquisition costs		_	_	_
	Policyholder dividends accrual				
	7. Fixed assets		6,810	-	6 910
	<ul><li>8. Compensation and benefit</li></ul>		0,810	-	6,810
	accruals		-	427	(427)
	9. Pension accruals		_	_	-
	10. Receivables – nonadmitted		_	_	_
	11. Net operating loss carry-forward		_	_	_
	12. Tax credit carry-forward		_	_	_
	13. Other		_	402,743	(402,743)
	14. Bad debts		11,745,061	5,973,532	5,771,529
	15. Accrued litigation		11,743,001	3,913,332	3,771,329
	16. CMS Rx reserve		2 501 126	1,590,508	1,000,618
			2,591,126	1,390,308	1,000,018
	17. CMS risk corridor -ACA		-	-	-
	18. Medicare risk adjustment data		-	-	-
	19. Miscellaneous reserves		6,511	73,291	(66,780)
	20. Accrued lease		-	-	-
	21. Section 197 intangible		-	-	-
	22. Premium rebates MER		-	-	-
	23. Provider contracts		774,602	1,417,657	(643,055)
	24. Premium acquisition expense		-	-	-
	99. Subtotal		29,207,634	17,218,874	11,988,760
b.	Statutory valuation allowance adjustment		_	_	_
c.	Nonadmitted		(278,133)	(587,494)	309,361
d.	Admitted Ordinary DTAs			16,631,380	
			28,929,501	10,031,360	12,298,121
e.	Capital		1 002 602	1 001 002	(000 100)
	1. Investments		1,082,693	1,891,882	(809,189)
	2. Net capital loss carry-forward		-	-	-
	3. Real estate		-	-	-
	4. Other		-	-	
c	99. Subtotal		1,082,693	1,891,882	(809,189)
f.	Statutory valuation allowance adjustment		(1,082,693)	(1,891,882)	809,189
~	Nonadmitted		(1,002,093)	(1,091,002)	009,109
g.	Admitted capital DTAs		<u>-</u>		<u>-</u> _
h.	*	Φ.	20.020.501	Φ 16 621 200	Ф 10.200.101
i.	Admitted DTAs	\$	28,929,501	\$ 16,631,380	\$ 12,298,121
DTLs resul	lting from Book/Tax Differences in:				
			December 31,	December	a.
a.	Ordinary		2023	31, 2022	Change
	1. Investments	\$	-	\$ -	\$ -
	2. Fixed assets		-	-	-
	3. Deferred and uncollected				
	premium 4. Policyholder reserves/salvage &		-	-	-
	subrogation		_	_	_
	5. Other		_	_	_
	6. Premium acquisition reserve		(4,391)	(4,923)	532
	7. CMS Rx reserve		(4,371)	(4,723)	332
			(17.705)	(2( 596)	0.061
	8. Reserve transition adjustment		(17,725)	(26,586)	8,861
	9. Accrued lease		<u> </u>	<del>-</del>	
	99. Subtotal		(22,116)	(31,509)	9,393
b.	Capital				
	1. Investments		-	-	-
	2. Real estate		-	-	-
	3. Other		-	-	-
	99. Subtotal		_	-	-
c.	DTLs	\$	(22,116)		\$ 9,393
			( ,/	(- 57)	. ,
(4) Net	t deferred tax asset/(liability)	\$	28,907,385	\$ 16,599,871	\$ 12,307,514

#### NOTES TO THE FINANCIAL STATEMENTS

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory Federal income tax rate to income before income taxes. The significant items causing this difference as of December 31, 2023 are as follows:

			Effective Tax
	 Amount	Tax Effect	Rate
Income before taxes	\$ 189,469,863	\$ 39,788,671	21.00%
Tax-exempt interest	(574,579)	(120,662)	(0.06%)
Dividends received deduction	-	-	0.00%
Proration	143,645	30,165	0.02%
Meals & entertainment, lobbying expenses, etc.	7,682	1,613	0.00%
Statutory valuation allowance adjustment Change to nonadmitted assets & deferred tax	-	-	0.00%
true-up	(5,117,590)	(1,074,694)	(0.57%)
Other, including prior year true-up	 10	2	0.00%
Total	\$ 183,929,031	\$ 38,625,095	20.39%
Federal income taxes incurred [expense/(benefit)]		\$ 51,600,812	27.23%
Tax on capital gains/(losses) Change in net deferred income tax		(977,564)	(0.52%)
[charge/(benefit)]		(11,998,153)	(6.32%)
Total statutory income taxes		\$ 38,625,095	20.39%

- E. Operating loss and tax credit carry-forwards and protective tax deposits
  - (1) At December 31, 2023, the Company had no net operating loss carry-forwards.

At December 31, 2023, the Company had no capital loss carry-forwards.

At December 31, 2023, the Company had no AMT credit carry-forwards.

(2) The following table demonstrates the income tax expense for 2022 and 2023 that is available for the recoupment in the event of future net losses:

	 Ordinary	ry Capital			Total
2022	56,610,447		(1,349,209)		55,261,238
2023	51,706,957		(977,564)		50,729,393
Total	\$ 108,317,404	\$	(2,326,773)	\$	105,990,631

- (3) There are no deposits admitted under IRC § 6603.
- F. The Company is included in a consolidated federal income tax return with its parent Company, Humana Inc. The Company has a written agreement, approved by the Company's Board of Directors, which sets forth the manner in which the total combined federal income tax is allocated to each entity which is a party to the consolidation. Pursuant to this agreement, the Company has the enforceable right to be paid for any future net losses it may incur. The Company has no contingent income tax liabilities. The Company has not adjusted gross deferred tax assets due to changes in judgment about the realizability of the related deferred tax asset. The Company has no deposits under Section 6603 of the Internal Revenue Code.

# HUMANA INC. AND SUBSIDIARIES INCLUDED IN 2023 CONSOLIDATED FEDERAL INCOME TAX RETURN

# CALENDAR YEAR ENDED DECEMBER 31, 2023 AFFILIATIONS SCHEDULE

# CORPORATE NAME AND EMPLOYER IDENTIFICATION NUMBER THE ADDRESS OF EACH COMPANY IS: P. O. BOX 740026, LOUISVILLE, KY 40201

CORP.	CORPORATION NAME	EMPLOYER IDENTIFICATION NUMBER
1,00		1,01,2221
		(1.0645500
1	HUMANA INC.	61-0647538
2	516-526 WEST MAIN STREET CONDOMINIUM COUNCIL OF CO-OWNERS INC.	5, 20-5309363
3	A & A HOMECARE INC.	03-0523544
4	ABERDEEN HOLDINGS, INC.	72-2695805
5	ABLE HOME HEALTHCARE, INC.	77-0601595
6	ADVANCED ONCOLOGY SERVICES, INC.	65-0180784
7	ALPINE HOME HEALTH CARE, LLC	36-4473376
8	AMERICAN HOMECARE MANAGEMENT CORP.	11-3306095

45-4020797

AMICUS MEDICAL CENTER, LLC

## NOTES TO THE FINANCIAL STATEMENTS

10		27 2074052
10 11	AMICUS MEDICAL GROUP, INC.	27-3974953 27-1085323
12	AMICUS MEDICAL SERVICES ORGANIZATION, LLC	20-1001348
13	ARCADIAN HEALTH PLAN, INC.	94-3247811
14	ASIAN AMERICAN HOME CARE, INC.	27-0287186
15	BALANCED HOME HEALTHCARE, INC. BRIDGES HOME HEALTH, INC.	20-1903568
16	CARENETWORK, INC.	39-1514846
17	CAREPLUS HEALTH PLANS, INC.	59-2598550
18	CARITEN HEALTH PLAN INC.	62-1579044
19	CENTERWELL CARE SOLUTIONS, INC.	85-0858631
20	CENTERWELL CERTIFIED HEALTHCARE CORP.	11-2645333
21	CENTERWELL HEALTH SERVICES (CERTIFIED), INC.	11-3454105
22	CENTERWELL HEALTH SERVICES HOLDING CORP.	11-3454104
23	CENTERWELL HEALTH SERVICES, INC.	36-4335801
24	CENTERWELL PHARMACY, INC.	61-1316926
25	CENTERWELL SENIOR PRIMARY CARE (AZ) CS, P.C.	93-2245383
26	CENTERWELL SENIOR PRIMARY CARE (FL), INC.	59-3164234
27	CENTERWELL SENIOR PRIMARY CARE (KS), P.A.	30-1236218
28	CENTERWELL SENIOR PRIMARY CARE (MO), P.C.	85-3676937
29	CENTERWELL SENIOR PRIMARY CARE (NC), P.C.	82-1926920
30	CENTERWELL SENIOR PRIMARY CARE (SC), P.C.	85-3577914
31	CENTERWELL SERVICES OF NEW YORK, INC.	11-2802024
32	CHA HMO, INC.	61-1279717 59-2531815
33	COMPBENEFITS COMPANY	04-3185995
34 35	COMPBENEFITS CORPORATION	36-3686002
36	COMPRENETTS DENTAL, INC.	58-2228851
37	COMPRENETTS DIRECT, INC.	74-2552026
38	COMPRENE CLINICAL MANAGEMENT INC.	45-3713941
39	CONVIVA HEALTH MANAGEMENT, INC.	46-5329373
40	CONVIVA HEALTH MANAGEMENT, LLC CONVIVA HEALTH MSO OF TEXAS, INC.	46-1225873
41	CONVIVA MEDICAL CENTER MANAGEMENT OF TEXAS, P.A.	47-1161014
42	DENTAL CARE PLUS MANAGEMENT, CORP.	36-3512545
43	DENTICARE, INC.	76-0039628
44	EAGLE RX HOLDCO, INC.	47-1407967
45	EAGLE RX, INC.	47-1416614
46	EDGE HEALTH MSO, INC.	84-2214810
47	EDGE HEALTH, P.C.	84-2752906
48	EMPHESYS INSURANCE COMPANY	31-0935772
49	EMPHESYS, INC.	61-1237697
50	ENCLARA PHARMACIA, INC.	23-3068914
51	FIRST HOME HEALTH, INC.	55-0750157
52	FOCUS CARE HEALTH RESOURCES, INC.	75-2784006
53	FPG ACQUISITION CORP.	81-3802918
54	FPG ACQUISITION HOLDINGS CORP.	81-3819187
55 56	FPG HOLDING COMPANY, LLC	32-0505460
56 57	GBA HOLDING, INC.	75-2855493 64-0730826
58	GILBERT'S HOME HEALTH AGENCY, INC.	39-1789830
59	GUIDANTRX, INC.	27-1649291
60	HARRIS, ROTHENBERG INTERNATIONAL INC.	42-1285486
61	HAWKEYE HEALTH SERVICES, INC. HEALTH VALUE MANAGEMENT, INC.	61-1223418
62	HHS HEALTHCARE CORP.	90-0527683
63	HOME HEALTH CARE AFFILIATES OF MISSISSIPPI, INC.	62-1775256
64	HOME HEALTH CARE AFFILIATES, INC.	74-2737989
65	HOME HEALTH OF RURAL TEXAS, INC.	75-2374091
66	HOME HEALTH SERVICES, INC.	87-0494759
67	HOMECARE HOLDINGS, INC.	65-0837269
68	HORIZON HEALTH CARE SERVICES, INC.	76-0456316
69	HUMANA ACTIVE OUTLOOK, INC.	20-4835394
70	HUMANA AT HOME (DALLAS), INC.	75-2739333
71	HUMANA AT HOME (HOUSTON), INC.	76-0537878
72	HUMANA AT HOME (SAN ANTONIO), INC	01-0766084
73	HUMANA AT HOME (TLC), INC.	75-2600512
74	HUMANA AT HOME 1, INC.	65-0274594
75 76	HUMANA AT HOME, INC.	13-4036798
76 77	HUMANA BENEFIT PLAN OF ILLINOIS, INC.	37-1326199
77 78	HUMANA BENEFIT PLAN OF SOUTH CAROLINA, INC.	84-3226630 75-2043865
10	HUMANA BENEFIT PLAN OF TEXAS, INC.	13-2043803

### NOTES TO THE FINANCIAL STATEMENTS

79	HUMANA DENTAL COMPANY	59-1843760
80	HUMANA DIGITAL HEALTH AND ANALYTICS PLATFORM SERVICES,	80-0072760
81	INC.	85-3099097
82	HUMANA DIRECT CONTRACTING ENTITY, INC.	46-4912173
83	HUMANA EAP AND WORK-LIFE SERVICES OF CALIFORNIA, INC. HUMANA EMPLOYERS HEALTH PLAN OF GEORGIA, INC.	58-2209549
84	HUMANA GOVERNMENT BUSINESS, INC.	61-1241225
85	HUMANA HEALTH BENEFIT PLAN OF LOUISIANA, INC.	72-1279235
86	HUMANA HEALTH COMPANY OF NEW YORK, INC.	26-2800286
87	HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC.	61-1041514
88	HUMANA HEALTH PLAN OF CALIFORNIA, INC.	26-3473328
89	HUMANA HEALTH PLAN OF OHIO, INC.	31-1154200
90	HUMANA HEALTH PLAN OF TEXAS, INC.	61-0994632
91	HUMANA HEALTH PLAN, INC.	61-1013183
92	HUMANA HEALTHCARE RESEARCH, INC.	42-1575099
93	HUMANA HOME ADVANTAGE (TX), P.A.	81-0789608
94	HUMANA INNOVATION ENTERPRISES, INC.	61-1343791
95 96	HUMANA INSURANCE COMPANY	39-1263473 61-1311685
90 97	HUMANA INSURANCE COMPANY OF KENTUCKY	20-2888723
98	HUMANA MARKETPOINT, INC.	61-1343508
99	HUMANA MARKETPOINT, INC. HUMANA MEDICAL PLAN OF MICHIGAN, INC.	27-3991410
100	HUMANA MEDICAL PLAN OF PENNSYLVANIA, INC.	27-4460531
101	HUMANA MEDICAL PLAN OF UTAH, INC.	20-8411422
102	HUMANA MEDICAL PLAN, INC.	61-1103898
103	HUMANA PHARMACY SOLUTIONS, INC.	45-2254346
104	HUMANA REAL ESTATE COMPANY	20-1724127
105	HUMANA REGIONAL HEALTH PLAN, INC.	20-2036444
106	HUMANA WISCONSIN HEALTH ORGANIZATION INSURANCE CORPORATION	39-1525003
107	HUMANADENTAL INSURANCE COMPANY	39-0714280
108	HUMANADENTAL, INC.	61-1364005
109	HUMCO, INC.	61-1239538
110	HUM-E-FL, INC.	61-1383567
111	INDEPENDENT CARE HEALTH PLAN	39-1769093
112	INTEGRACARE HOLDINGS, INC.	20-8781607
113	INTEGRACARE HOME HEALTH SERVICES, INC.	75-2865632
114	INTEGRACARE INTERMEDIATE HOLDINGS, INC.	20-8781715
115	KENTUCKY HOMECARE HOLDINGS, INC.	82-3695166
116	KENTUCKY HOMECARE PARENT INC.	82-3986306
117 118	MANAGED CARE INDEMNITY, INC.	61-1232669 65-0277280
119	MEDICAL CROUP AT SUN CITY (IOPAL), D.C.	88-0386657
120	MEDICAL GROUP AT SUN CITY (IQBAL), P.C. MEDICAL GROUP AT SUN CITY HOSPITALISTS (NAJMI), P.C.	84-3377726
121	MED-TECH SERVICES OF DADE, INC.	65-1033439
122	MED-TECH SERVICES OF PALM BEACH, INC.	65-0644307
123	METCARE OF FLORIDA, INC.	65-0879131
124	METROPOLITAN HEALTH NETWORKS, INC.	65-0635748
125	MISSOURI HOME CARE OF ROLLA, INC.	43-1317147
126	M-SAC, INC.	20-5123865
127	NEW YORK HEALTHCARE SERVICES, INC.	22-2695367
128	NURSING CARE-HOME HEALTH AGENCY, INC.	55-0633030
129	PBM HOLDING COMPANY	61-1340806
130	PBM PLUS MAIL SERVICE PHARMACY, LLC	20-2373204
131	PHH ACQUISITION CORP.	20-5043135
132 133	PHHC ACQUISITION CORP.	38-3784032 62-1552091
134	PHP COMPANIES, INC.	62-1250945
135	PREFERRED HEALTH PARTNERSHIP, INC. QC-MEDI NEW YORK, INC.	11-2750425
136	QUALITY CARE - USA, INC.	11-2256479
137	QUALITY LIVING HOME HEALTH CARE, LLC	45-2823888
138	ROHC, L.L.C.	75-2844854
139	SENIOR HOME CARE, INC.	59-3080333
140	SENIORBRIDGE FAMILY COMPANIES (FL), INC.	65-1096853
141	SENIORBRIDGE FAMILY COMPANIES (NY), INC.	36-4484443
142	SHC HOLDING, INC.	42-1699530
143	SOUTHERN NEVADA HOME HEALTH CARE, INC.	87-0494757
144	SYNERGY HOME CARE-ACADIANA REGION, INC.	72-1487473 20-1376846
145 146	SYNERGY HOME CARE-CAPITOL REGION, INC.	20-13/6846 36-4516940
1 10	SYNERGY HOME CARE-CENTRAL REGION, INC.	55 1510940

#### NOTES TO THE FINANCIAL STATEMENTS

147	SYNERGY HOME CARE-NORTHEASTERN REGION, INC.	72-1178497
148	SYNERGY HOME CARE-NORTHSHORE REGION, INC.	72-1223659
149	SYNERGY HOME CARE-NORTHWESTERN REGION, INC.	72-1431394
150	SYNERGY HOME CARE-SOUTHEASTERN REGION, INC.	72-1429305
151	SYNERGY, INC.	93-3419676
152	TEXAS DENTAL PLANS, INC.	74-2352809
153	THE DENTAL CONCERN, INC.	52-1157181
154	TRANSCEND COMMUNITY PHYSICIAN NETWORK (AR), P.A.	47-2770181
155	TRANSCEND COMMUNITY PHYSICIAN NETWORK (KS), P.A.	47-2111323
156	TRANSCEND COMMUNITY PHYSICIAN NETWORK, P.C.	47-2750105
157	TRILOGY HOME HEALTHCARE NE FL, INC	81-3442232
158	TRILOGY HOME HEALTHCARE SW FL, INC	81-4466479
159	VAN WINKLE HOME HEALTH CARE, INC.	62-1669388
160	VITALITY HHS HOLDINGS, INC.	81-2022629
161	VITALITY HOME CARE, INC	81-2019673
162	VOYAGER HOME HEALTH, INC.	26-1501792
163	VOYAGER HOSPICECARE, INC.	20-1173787

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

#### 10. Information Concerning Parent, Subsidiaries and Affiliates

A.-B. The Company has several management contracts with Humana Inc. and other related parties whereby the Company is provided with medical and executive management, information systems, claims processing, billing and enrollment, and telemarketing and other services as required by the Company. Management fees charged to operations for the years ended December 31, 2023 and 2022 were \$626,005,769 and \$627,245,352, respectively. As a part of this agreement, Humana Inc. makes cash disbursements on behalf of the Company which includes, but is not limited to, medical related items, general and administrative expenses, commissions and payroll. The Company continues to be primarily liable for any outstanding payments made on behalf of the Company, should Humana Inc. not be able to fulfill its obligations.

In the ordinary course of business, the Company also directly contracts with related parties to provide services that are routine in nature to its members. The administrative services, access fees, and cost of care services provided are determined within each individual agreement. The following table identifies the amount for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2023 and 2022, which meet the disclosure requirements pursuant to SSAP No. 25, *Affiliate and Other Related Parties* (SSAP No. 25):

	<u>2023</u>		<u>2022</u>
SeniorBridge and Humana At Home	\$ 53,781,449	\$	50,810,504
CenterWell Senior Primary Care Inc.	75,831,886		65,096,391
CenterWell Home Health	33,780,886		33,278,284
One Home Medical Equipment, LLC	65,077,901		43
Total	\$ 228,472,122	\$	149,185,222

In addition to the related parties above, the Company also has a contracted relationship with Humana Pharmacy Solutions, Inc. (HPS). HPS is responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims for Humana entities. HPS has various contracts with pharmacy manufacturers to provide the Company with purchase discounts and volume rebates on certain prescription drugs utilized by its members. The Company has an agreement with HPS to collect pharmacy rebates on its behalf and remit them to the Company on a monthly basis. The Company had \$2,451,963,996 and \$2,013,814,602 of administrative service and prescription costs in 2023 and 2022, respectively, with HPS. The prescription costs included in fees paid to HPS are gross of the pharmacy rebates that the Company receives, see Footnote 28, and also includes payments for Medicare Part D claims that CMS reimburses the Company for through the Coverage Gap, Low Income and Reinsurance subsidies.

Included in the payments to HPS are also costs incurred from Humana Pharmacy, Inc. Humana Pharmacy, Inc. provides covered members with prescription services through use of the mail order as well as brick and mortar locations. These services are limited to maintenance medication prescription drug and allied services and supplies normally provided to the general public in the ordinary course of pharmacy business. The Company had \$695,624,390 and \$656,793,635 of prescription costs in 2023 and 2022, respectively, with Humana Pharmacy, Inc.

No dividends or returns of capital were paid by the Company as of December 31, 2023.

### C. (1) Detail of Material Related Party Transactions

					Written		Reporting
					Agreeme		Period Date
Reference		Name of	Name of	Type of	nt	Due	Amount Due
#	Date of Transaction	Related Party	Relationship	Transaction	(Yes/No)	Date	From (To)
		PMR		Other			
		Virginia		Transactions			
	1/1/2023 -	Holding LLC		Involving			
1	12/31/2023	(JenCare)	Provider	Services	Yes	Net 30	\$(4,582,784)

#### **NOTES TO THE FINANCIAL STATEMENTS**

(2) Detail of Material Related Party Transactions Involving Services

				Amount Based on	Amount Charged	
Reference		Overview	Amount	Allocation of Costs	Modified or Waived	
#	Name of Related Party	Description	Charged	or Market Rates	(Yes/No)	
	PMR Virginia Holding	Provider Services				
1	LLC (JenCare)	to Members	\$102,416,482	\$102,416,482	No	

(3) Detail of Material Related Party Transactions Exchange of Assets and Liabilities

Not Applicable.

(4) Detail of Amounts Owed To/From a Related Party

			Aggregate		Net Amount	
		Aggregate	Reporting	Amount Offset in	Recoverable /	
Reference		Reporting Period	Period Amount	Financial Statement	(Payable) by	Admitted
#	Name of Related Party	Amount Due From	(Due To)	(if Qualifying)	Related Party	Recoverable
	PMR Virginia Holding					_
1	LLC (JenCare)	\$-	\$(4,582,784)	\$-	\$(4,582,784)	\$-

- D. At December 31, 2023, the Company reported \$8,713,849 due from Humana Inc. Amounts due to or from parent are generally settled within 90 days.
- E. Not Applicable.
- F. Not Applicable.
- G. All outstanding shares of the Company are owned by the Parent Company.
- H. Not Applicable.
- I. Not Applicable.
- J. Not Applicable.
- K. Not Applicable.
- L. Not Applicable.
- M. All SCA Investments

Not Applicable.

N. Investment in Insurance SCA

Not Applicable.

O. SCA Loss Tracking

Not Applicable.

#### 11. <u>Debt</u>

A. Debt Including Capital Notes

The Company has no debentures outstanding.

The Company has no capital notes outstanding.

The Company does not have any reverse repurchase agreements.

B. Federal Home Loan Bank (FHLB) Agreements

The Company does not have any FHLB agreements.

- 12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans
  - A.-D. Defined Benefit Plans

Not Applicable.

E. Defined Contribution Plans

Not Applicable.

F. Multiemployer Plans

#### NOTES TO THE FINANCIAL STATEMENTS

G. Consolidated/Holding Company Plans

The Company employees are eligible to participate in the Humana Retirement and Savings Plan ("the Plan"), a defined contribution plan, sponsored by Humana Inc. The Plan maintains two accounts, the Savings Account and the Retirement Account.

Humana Inc.'s total contributions paid to the Savings and Retirement accounts of the Humana Retirement Savings Plan were \$276,415,225 and \$270,539,838 for the years ended December 31, 2023 and 2022, respectively. Of these contributions, the Company contributed \$(106) and \$5,734 during 2023 and 2022, respectively. As of December 31, 2023 and 2022, the fair market value of the Humana Retirement Savings Plan's assets was \$7,361,090,600 and \$6,432,021,537, respectively.

H. Postemployment Benefits and Compensated Absences

Not Applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not Applicable.

- 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations
  - A. The Company has \$16.667 par value common stock with 60,000 shares authorized and 60,000 shares issued and 60,000 outstanding. All shares are common stock shares.
  - B. The Company has no preferred stock outstanding.
  - C.-E. Dividends and returns of capital to shareholders are noncumulative and are paid as determined by the Board of Directors. In accordance with the Office statutes, the maximum amount which can be paid by the Company to shareholders without prior approval by the Office is the lesser of 10% of total surplus, or the greater of net operating gain for the calendar year preceding the dividend or for the 3 calendar years preceding the dividend less dividends paid for the most recent 2 of those calendar years. All ordinary dividends are limited to available and accumulated surplus funds. Any dividends paid in the twelve months preceding a proposed dividend are considered in determining whether a dividend is extraordinary. Based on these restrictions, the Company could have paid a maximum dividend or return of capital to shareholders of approximately \$93,029,000 in 2023 without prior regulatory approval.

Within the limitations above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.

No dividends or returns of capital were paid by the Company as of December 31, 2023.

- F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. Not Applicable.
- H. Not Applicable.
- Not Applicable.
- J. The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is \$3,853,282.
- K. Not Applicable.
- Not Applicable.
- M. Not Applicable.
- 14. Liabilities, Contingencies and Assessments
  - A. Contingent Commitments

Not Applicable.

B. Assessments

Not Applicable.

C. Gain Contingencies

Not Applicable.

D. Claims related extra contractual obligation and bad faith losses stemming from lawsuits

Not Applicable.

E. Joint and Several Liabilities

#### NOTES TO THE FINANCIAL STATEMENTS

#### F. All Other Contingencies

During the ordinary course of business, the Company is subject to pending and threatened legal actions. Management of the Company does not believe that any of these actions will have a material adverse effect on the Company's surplus, results of operations or cash flows. However, the likelihood or outcome of current or future legal proceedings cannot be accurately predicted, and they could adversely affect the Company's surplus, results of operations and cash flows.

The Company is not aware of any other material contingent liabilities as of December 31, 2023.

#### 15. Leases

Not Applicable.

#### Information about Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of <u>Credit Risk</u>

The Company has no investment in Financial Instruments with Off-Balance Sheet Risk or Concentrations of Credit Risk.

#### 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not Applicable.

B. Transfer and Servicing of Financial Assets

Not Applicable.

C. Wash Sales

Not Applicable.

#### 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

Not Applicable.

B. ASC Plans

Not Applicable.

- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract
  - (1) The Company records no revenue explicitly attributable to the cost share and reinsurance components of its Medicare or other similarly structured cost based reimbursement contracts.
  - (2) As of December 31, 2023, the Company has recorded a receivable from CMS of \$892,035 related to the cost share and reinsurance components of administered Medicare products. The Company does not have any receivables greater than 10% of the Company's accounts receivable from uninsured accident and health plans or \$10,000.
  - (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or other similarly structured cost based reimbursement contracts, the Company has recorded no allowances and reserves for adjustment of recorded revenues and receivables.
  - (4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.

#### 19. <u>Direct Premium Written/Produced by Managing General Agents/Third Party Administrators</u>

Not Applicable.

#### 20. Fair Value Measurements

A. (1) The fair value of financial assets at December 31, 2023 were as follows:

Level 1									
Level I			Level 2		Level 3		Value (NAV)		Total
\$	-	\$	-	\$	-	\$	-	\$	-
	-		79,895		-		-		79,895
	-		2,217		-		-		2,217
	-		36,317,682		-		-		36,317,682
	-		36,399,794		-		-		36,399,794
\$	-	\$	36,399,794	\$	_	\$	-	\$	36,399,794
\$	-	\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-	\$	-
	\$	\$ - - -	\$ - \$ - - -	\$ - \$ - 79,895 - 2,217 - 36,317,682 - 36,399,794 \$ - \$ 36,399,794 \$ - \$ - \$ - \$	\$ - \$ - \$ - 79,895 - 2,217 - 36,317,682 - 36,399,794 \$ - \$ 36,399,794 \$ - \$ 36,399,794 \$ - \$ 5	\$ - \$ - \$ - \$ - \$ - 79,895 \$ - 36,317,682 36,399,794 - \$ - \$ 36,399,794 \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$	\$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ -	\$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ -	\$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ - \$ -

Net Asset

#### NOTES TO THE FINANCIAL STATEMENTS

The Company reports transfers between Level 1 and Level 2 of the fair value hierarchy levels at the end of the reporting period. There were no transfers between Level 1 and Level 2 of the fair value hierarchy between December 31, 2022 and December 31, 2023.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Not Applicable.

- (3) The Company reports transfers into or out of Level 3 of the fair value hierarchy levels at the end of the reporting period. There were no transfers into or out of Level 3 of the fair value hierarchy levels between December 31, 2022 and December 31, 2023.
- (4) Fair value of actively traded debt securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. The Company generally obtains one quoted price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates and prepayment speeds. The Company is responsible for the determination of fair value and as such, the Company performs analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by the Company's third party investment advisor. Based on the Company's internal price verification procedures and review of fair value methodology documentation provided by the third party pricing service, there were no material adjustments to the prices obtained from the third party pricing service during the year ended December 31, 2023.
- (5) Derivative Fair Values

Not Applicable.

B. Other Fair Value Disclosures

Not Applicable.

C. Fair Values for All Financial Instruments by Levels 1, 2 and 3

Type of Financial										Net Asset		Not Practicable	
Instrument	Aggı	egate Fair Value	Ad	mitted Assets		Level 1		Level 2	Level 3		Value (NAV	7)	(Carrying Value)
Bonds, short-													
term investments													
and cash													
equivalents	\$	1,674,671,662	\$	1,802,435,838	\$	259,249,258	\$	1,415,422,404	\$	-	\$	- 5	\$ -

D. Financial Instruments for which Not Practicable to Estimate Fair Values

Not Applicable.

#### 21. Other Items

A. Extraordinary Items

The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted the Company's business. During periods of increased incidences of COVID-19, there was a reduction in non-COVID-19 hospital admissions and lower overall healthcare system consumption that decreased utilization. Likewise COVID-19 treatment and testing costs increased utilization. During 2022, the Company experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted the Company's ability to implement clinical initiatives to manage health care costs and chronic conditions of its members, and appropriately document their risk profiles, and, as such, affecting 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted claim reserve development and operating cash flows for 2021.

The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.

B. Troubled Debt Restructuring: Debtors

Not Applicable.

C. Other Disclosures and Unusual Items

Not Applicable.

D. Business Interruption Insurance Recoveries

#### NOTES TO THE FINANCIAL STATEMENTS

E. State Transferable and Non-transferable Tax Credits

Not Applicable.

- F. Subprime Mortgage Related Risk Exposure
  - (1) The Company consults with its external investment managers to assess its subprime mortgage related risk exposure. Certain characteristics are utilized to determine if a mortgage-backed security has subprime exposure. The main characteristics reviewed when determining this are the collateral and structure of the security, the loan purpose, loan documentation, occupancy, geographical location, loan size and type. Subprime mortgage borrowers typically have lower credit scores, lower loan balances and higher loan-to-values than other conforming loans. Management's practices include reviewing quantitative and qualitative credit models that analyze loan-level collateral composition, historical underwriter performance trends, the impact of macroeconomic factors, and issuer risks; as well as reviewing the estimation of security cash flows and monthly model calibrations.
  - (2) Direct exposure through investments in sub-prime mortgage loans.

The Company has no direct exposure through investment to sub-prime mortgage loans.

- (3) Direct exposure through other investments:
  - a. Residential mortgage backed securities No substantial exposure noted.
  - b. Commercial mortgage backed securities No substantial exposure noted.
  - Collateralized debt obligations No substantial exposure noted.
  - $d. \quad Structured \ securities No \ substantial \ exposure \ noted.$
  - e. Equity investment in SCAs No substantial exposure noted.
  - f. Other assets No substantial exposure noted.
  - g. Total No substantial exposure noted.
- (4) Underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty coverage, Financial Guaranty coverage, Directors and Officers liability coverage, or Errors and Omissions liability coverage.

The Company does not have sub-prime mortgage risk.

Classification of mortgage related securities is primarily based on information from outside data services, including rating agency actions. When considering our exposure, the Company evaluated the percentage of full documentation loans, percent of owner occupied properties, FICO scores, average margin for ARM loans, percent of loans with prepayment penalties, the existence of non-traditional underwriting standards, among other factors.

G. Retained Assets

Not Applicable.

H. Insurance Linked Securities

Not Applicable.

#### 22. Events Subsequent

The Company is not aware of any events or transactions occurring subsequent to the close of the books for this statement which may have a material effect on its financial condition. Subsequent events have been considered through February 29, 2024 for the Statutory Statement issued on February 29, 2024.

#### 23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10.0 percent or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10.0 percent or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Section 2 – Ceded Reinsurance Report – Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

$$Yes\left( \ \right) \ No\left( \ X \ \right)$$

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

## STATEMENT AS OF December 31, 2023 OF Arcadian Health Plan, Inc.

#### NOTES TO THE FINANCIAL STATEMENTS

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes ( ) No ( X )

B. Uncollectible Reinsurance

Not Applicable.

C. Commutation of Ceded Reinsurance

Not Applicable.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not Applicable.

#### 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

- A. The Company estimates accrued retrospective premium adjustments for its Medicare business through a mathematical approach using an algorithm based upon settlement procedures defined by contracts with CMS.
- B. The Company records accrued retrospective premium as an adjustment to earned premiums.
- C. The amount of net premiums written by the Company at December 31, 2023 that are subject to retrospective rating features was \$7,734,857,401, or 100.00% of the total net premiums written. No other net premiums written by the Company are subject to retrospective rating features.
- D. Medical loss ratio rebates required pursuant to the Public Health Service Act

Not Applicable.

E. Risk Sharing Provisions of the Affordable Care Act

Not Applicable.

## 25. Change in Incurred Claims and Claim Adjustment Expenses

Benefits and loss adjustment expenses payable, net of health care receivables, as of December 31, 2022, were \$566,619,903. As of December 31, 2023, \$450,410,504 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$42,938,993 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$73,270,407 favorable prior-year development since December 31, 2022. The decrease is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Included in this decrease, the Company experienced \$73,270,407 of favorable prior year claim development on retrospectively rated policies. However, the business to which it relates is subject to premium adjustments.

26. <u>Intercompany Pooling Arrangements</u>

Not Applicable.

### 27. Structured Settlements

The Company has no structured settlements.

## STATEMENT AS OF December 31, 2023 OF Arcadian Health Plan, Inc.

## **NOTES TO THE FINANCIAL STATEMENTS**

## 28. <u>Health Care Receivables</u>

## A. Pharmaceutical Rebate Receivables

	Estimate Pharmacy	P	harmacy Rebates		Actual Rebates	Actual Rebates
	Rebates as Reported	i	as Billed or	Actual Rebates	Received Within 91	Received More
	on Financial		Otherwise	Received Within	to 180 Days of	than 181 Days
Quarter	Statements		Confirmed	90 Days of Billing	Billing	after Billing
12/31/2023	\$ 158,340,122	2 \$	158,340,122	\$ -	\$ -	\$ -
9/30/2023	155,994,51	5	154,565,383	152,001,806	3,173	-
6/30/2023	184,011,63	7	177,205,629	177,258,092	315,399	-
3/31/2023	179,821,52	3	175,592,477	172,598,203	970,905	-
12/31/2022	131,966,284	4	127,566,741	116,236,051	10,628,334	-
9/30/2022	142,784,21	5	136,651,765	137,180,235	(528,470)	-
6/30/2022	167,818,54	5	166,532,203	165,206,084	1,326,119	-
3/31/2022	163,031,38	1	145,036,888	135,071,333	1,120,794	8,844,761
12/31/2021	133,869,323	3	132,556,063	132,433,978	122,085	-
9/30/2021	139,264,55	1	137,652,539	135,444,227	1,942,812	265,500
6/30/2021	165,379,68	1	164,765,842	163,838,976	4,163	922,703
3/31/2021	128,534,860	)	134,264,627	134,021,333	750	242,544

December 31, 2023

## B. Risk Sharing Receivables

Not Applicable.

## 29. Participating Policies

The Company has no participating policies.

2. Date of the most recent evaluation of this liability

## 30. Premium Deficiency Reserves

1. Liability carried for premium deficiency reserves \$ 17,301,701

3. Was anticipated investment income utilized in the calculation? Yes ( X ) No ( )

## 31. Anticipated Salvage and Subrogation

Not Applicable.

## **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company Sy is an insurer?					Yes [ )	Х]	No [	]
10	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.	Ingurance Com	missioner Director or C	tunorintondont or with					
1.2	If yes, did the reporting entity register and file with its domiciliary State such regulatory official of the state of domicile of the principal insurer i providing disclosure substantially similar to the standards adopted by its Model Insurance Holding Company System Regulatory Act and mo subject to standards and disclosure requirements substantially similar	n the Holding Co the National Ass del regulations	ompany System, a regis sociation of Insurance Copertaining thereto, or is	stration statement ommissioners (NAIC) in the reporting entity	. Yes [ X	] No [	]	N/A	[ ]
1.3	State Regulating?					Washi	ngtor	ı	
1.4	Is the reporting entity publicly traded or a member of a publicly traded	group?				Yes [ )	<b>X</b> ]	No [	]
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code	issued by the S	SEC for the entity/group.			00000	4907	1	
2.1	Has any change been made during the year of this statement in the charge reporting entity?					Yes [ )	Κ]	No [	]
2.2	If yes, date of change:					01/19	/2023	3	
3.1	State as of what date the latest financial examination of the reporting e	entity was made	or is being made			12/31	/2020	)	
3.2	State the as of date that the latest financial examination report becamentity. This date should be the date of the examined balance sheet an					12/31	/2020	)	
3.3	State as of what date the latest financial examination report became a domicile or the reporting entity. This is the release date or completion examination (balance sheet date).	date of the exar	nination report and not t	the date of the		06/07	/2022	2	
3.4	By what department or departments? The Washington Department of Insurance								
3.5	Have all financial statement adjustments within the latest financial exastatement filed with Departments?	mination report	been accounted for in a	subsequent financial	. Yes [ X	] No [	]	N/A	[ ]
3.6	Have all of the recommendations within the latest financial examination	n report been co	omplied with?		. Yes [ X	] No [	]	N/A	[ ]
4.1		yees of the repo measured on di es of new busine	orting entity), receive cre rect premiums) of: ess?	edit or commissions for or	control	Yes [	]	No [	Х ]
4.2	During the period covered by this statement, did any sales/service org receive credit or commissions for or control a substantial part (more the premiums) of:	anization owned an 20 percent o	d in whole or in part by the fany major line of busir	ness measured on direct	iffiliate,	Yes [	]	No [	X ]
						Yes [ Yes [			
5.1	Has the reporting entity been a party to a merger or consolidation during the second file the merger history data file with the NAIC.	ng the period co	vered by this statement	?		Yes [	]	No [	Х]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state ceased to exist as a result of the merger or consolidation.	of domicile (use	e two letter state abbrev	riation) for any entity that	has				
	1 Name of Entity		2 NAIC Company Code	3 State of Domicile					
6.1	Has the reporting entity had any Certificates of Authority, licenses or rerevoked by any governmental entity during the reporting period?	egistrations (incl	luding corporate registra	ation, if applicable) suspe		Yes [	]	No [	Х ]
6.2	If yes, give full information:								
7.1	Does any foreign (non-United States) person or entity directly or indire	ctly control 10%	or more of the reporting	g entity?		Yes [	]	No [	Х ]
7.2	If yes,						0.0		
	<ul><li>7.21 State the percentage of foreign control;</li></ul>	ne entity is a mu	tual or reciprocal, the na	ationality of its manager o			0.0		%
	1 Nationality		2 Type of Er	ntity					
	Nationality	+	i ype di Ei	inity					

8.1 8.2	Is the company a subsidiary of a depository institution holding company of the response to 8.1 is yes, please identify the name of the DIHC.					Yes [	]	No [	[ X ]	
	Not Applicable					., .				
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fir If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	(city and state of the main office) of any affiliates r Office of the Comptroller of the Currency (OCC), the	egulated ne Federa	by a fe	deral	Yes [	J	No [	. X ]	
	1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC					
							╛			
8.5 8.6	Is the reporting entity a depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding response to 8.5 is no, is the reporting entity a company or subsidiary	olding company?of a company that has otherwise been made subje	ct to the			Yes [	-			
•	Federal Reserve Board's capital rule?				res [	] No [	X ]	N/F	ΑĮ	J
9.	What is the name and address of the independent certified public according PricewaterhouseCoopers LLC, 500 West Main Street, Suite 1800, Lo	9								
10.1	Has the insurer been granted any exemptions to the prohibited non-aurequirements as allowed in Section 7H of the Annual Financial Reportillaw or regulation?	dit services provided by the certified independent p ng Model Regulation (Model Audit Rule), or substa	ublic acc	ountan nilar sta	t ate	Yes [	]	No [	( X ]	
10.2	, , , , ,									
10.3	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exemption	nilar state law or regulation?	Regulation	on as		Yes [	]	No [	[ X ]	
10.5	Has the reporting entity established an Audit Committee in compliance	with the domiciliary state insurance laws?			Yes [ X	] No [	]	N/A	Α[	]
10.6	If the response to 10.5 is no or n/a, please explain.									
11. 12.1	12.12 Number of par	ication?  Y 40202  mpany or otherwise hold real estate indirectly?  estate holding company  cels involved				0				
		usted carrying value				\$				0
12.2	If yes, provide explanation									
10	FOR LIMITED STATES PRANCIES OF ALIEN REPORTING ENTITIE									
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES What changes have been made during the year in the United States m		ag ontity?	•						
	Not Applicable.									
13.2	, ,					Yes [	-	No [		
13.3 13.4	Have there been any changes made to any of the trust indentures during If answer to (13.3) is yes, has the domiciliary or entry state approved the					Yes [	-	-		1
14.1	Are the senior officers (principal executive officer, principal financial off					] No [	]	IN/ F	4 [ X	J
	similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual or relationships;  b. Full, fair, accurate, timely and understandable disclosure in the period	ch includes the following standards?or apparent conflicts of interest between personal a	ind profe			Yes [ X	. ]	No [	. 1	
	c. Compliance with applicable governmental laws, rules and regulation		ıty,							
	d. The prompt internal reporting of violations to an appropriate person of									
	e. Accountability for adherence to the code.	, , , , , , , , , , , , , , , , , , , ,								
14.11	If the response to 14.1 is No, please explain:									
14.0	Has the eads of othics for conjur managers been amended?					Var I V	, 1	Ma !	r 1	
	Has the code of ethics for senior managers been amended?					Yes [ X	. ]	NO [	. 1	
.7.41	Ethics Every Day was amended in June 2023 to update content based		essary ar	nd perfo	orm					
	general document maintenance.									
14.3	· · · · · · · · · · · · · · · · · · ·	pecified officers?				Yes [	]	No [	[ X ]	
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).									

ſ	4		1	3		
	1 American Bankers Association	2		3	4	
	(ABA) Routing Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit	Amo	
L						
		BOAR	D OF DIRECTOR	s		
		or sale of all investments of the reporting entity passed	upon either by the board	of directors or a subordinate committee	Yes [ X	] No [
[	Does the reporti	ng entity keep a complete permanent record of the pro	ceedings of its board of dir	rectors and all subordinate committees	Yes [ X	
-	part of any of its	g entity an established procedure for disclosure to its b officers, directors, trustees or responsible employees t	hat is in conflict or is likely	to conflict with the official duties of such	Yes [ X	1 No [
,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				.00 [ //	, [
			FINANCIAL			
I	Has this stateme	ent been prepared using a basis of accounting other that ciples)?	an Statutory Accounting Pr	rinciples (e.g., Generally Accepted	Yes [	1 No [
		aned during the year (inclusive of Separate Accounts, e				
				20.12 To stockholders not officers 20.13 Trustees, supreme or grand (Fraternal Only)	•	
		loans outstanding at the end of year (inclusive of Sepa	rate Accounts, exclusive o	ıf ,		
ı	oolicy loans):			20.21 To directors or other officers		
				20.22 To stockholders not officers20.23 Trustees, supreme or grand	•	
۱ ۱	Were any assets	s reported in this statement subject to a contractual obli reported in the statement?	igation to transfer to anoth	(Fraternal Only)er party without the liability for such		
		amount thereof at December 31 of the current year:		21.21 Rented from others	\$	
	•	•		21.22 Borrowed from others	\$	
				21.23 Leased from others		
				21.24 Other	\$	
l ç	Does this staten guaranty associa	nent include payments for assessments as described in ation assessments?			Yes [	] No [
2	f answer is yes:			2.21 Amount paid as losses or risk adjustmer		
				2.22 Amount paid as expenses		
				2.23 Other amounts paid		
		ng entity report any amounts due from parent, subsidia				
[	Does the insure	ny amounts receivable from parent included in the Pag utilize third parties to pay agent commissions in which	the amounts advanced by	y the third parties are not settled in full within	\$	
		o 24.1 is yes, identify the third-party that pays the agen			103 [	, 140 [
Ī			Is the	4		
			Third-Party Ag a Related Par			
		Name of Third-Party	(Yes/No)			
Į						
			NVESTMENT			

25.02	2 If no, give full and complete information, relating thereto						
25.03	3 For securities lending programs, provide a description of the program inc whether collateral is carried on or off-balance sheet. (an alternative is to r N/A	reference Note 17 where this information is also provided)					
25.04	For the reporting entity's securities lending program, report amount of col Instructions.		\$			0	
25.05	For the reporting entity's securities lending program, report amount of col	lateral for other programs.	\$			0	
25.06	Does your securities lending program require 102% (domestic securities) outset of the contract?	and 105% (foreign securities) from the counterparty at theYes [	] No	[ ]	N/A [	Х]	
25.07	7 Does the reporting entity non-admit when the collateral received from the	Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%?					
25.08	Does the reporting entity or the reporting entity's securities lending agent conduct securities lending?	utilize the Master Securities lending Agreement (MSLA) to Yes [	] No	[ ]	N/A [	Х ]	
25.09	9 For the reporting entity's securities lending program state the amount of t	he following as of December 31 of the current year:					
	25.092 Total book/adjusted carrying value of reinvested	oorted on Schedule DL, Parts 1 and 2collateral assets reported on Schedule DL, Parts 1 and 2he liability page	\$			0	
26.1	Were any of the stocks, bonds or other assets of the reporting entity own control of the reporting entity or has the reporting entity sold or transferred force? (Exclude securities subject to Interrogatory 21.1 and 25.03)	d any assets subject to a put option contract that is currently in	Yes [	X ] 1	No [	]	
26.2	If yes, state the amount thereof at December 31 of the current year:	26.21 Subject to repurchase agreements	\$ \$ \$ \$ to	1	12,011	0 0 0 0 0 ,049	
		26.31 Pledged as collateral to FHLB - including assets backing funding agreements	\$			0	
26.3	For category (26.26) provide the following:						
26.3	1 Nature of Restriction	2 Description		3 nount		]	
26.3	1 Nature of Restriction			nount		]	
26.3	Nature of Restriction  Does the reporting entity have any hedging transactions reported on School	Description	Yes [	nount	No [ X	•	
27.1 27.2	Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholl fyes, has a comprehensive description of the hedging program been malf no, attach a description with this statement.	Description  edule DB?  ade available to the domiciliary state?	Yes [	nount	No [ X		
27.1 27.2 JINES 2	Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholl figure yes, has a comprehensive description of the hedging program been mail figure no, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY	Description  edule DB?	Yes [ ] No	] N	No [ X N/A [		
27.1 27.2 LINES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholif yes, has a comprehensive description of the hedging program been mails fino, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY Does the reporting entity utilize derivatives to hedge variable annuity guarantees.	Description  edule DB?	Yes [ ] No	nount	No [ X N/A [		
27.1 27.2 JINES 2	Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholl fyes, has a comprehensive description of the hedging program been may lift no, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY Does the reporting entity utilize derivatives to hedge variable annuity guar lift the response to 27.3 is YES, does the reporting entity utilize:  27.41 Specience 27.42 Perm	Description  edule DB?	Yes [ ] No  Yes [ Yes [ Yes [	] N	No [ X N/A [		
27.1 27.2 LINES 2 27.3	Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholif yes, has a comprehensive description of the hedging program been mail fino, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY Does the reporting entity utilize derivatives to hedge variable annuity guar If the response to 27.3 is YES, does the reporting entity utilize:  27.41 Special 27.42 Perm 27.43 Other	Description  dedule DB?	Yes [  Yes [  Yes [  Yes [  Yes [  Yes [	] N ] N ] N ] N	No [ X N/A [ No [ No [ No [ No [		
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  Nature of Restriction  Does the reporting entity have any hedging transactions reported on Scholing Scholi	Description  redule DB?	Yes [  Yes [  Yes [  Yes [  Yes [  Yes [	] N ] N ] N ] N	No [ X N/A [ No [ No [ No [ No [	•	
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  If yes, has a comprehensive description of the hedging program been may lift no, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY  Does the reporting entity utilize derivatives to hedge variable annuity guars  If the response to 27.3 is YES, does the reporting entity utilize:  27.41 Special 27.42 Perm 27.43 Other  By responding YES to 27.41 regarding utilizing the special accounting profollowing:  The reporting entity has obtained explicit approval from the domi  Hedging strategy subject to the special accounting provisions is  Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within the Financial Officer Certification has been obtained which indicates Hedging Strategy within VM-21 and that the Clearly Defined Hed its actual day-to-day risk mitigation efforts.	edule DB?	Yes [	] N ] N ] N ] N	No [ X N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ N/A [	X ]  1  1  1  1  1	
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction  If yes, has a comprehensive description of the hedging program been may lif no, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY Does the reporting entity utilize derivatives to hedge variable annuity guar lift the response to 27.3 is YES, does the reporting entity utilize:  27.41 Special 27.42 Perm 27.43 Other  By responding YES to 27.41 regarding utilizing the special accounting profollowing:  The reporting entity has obtained explicit approval from the domi Hedging strategy subject to the special accounting provisions is  Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within Financial Officer Certification has been obtained which indicates Hedging Strategy within VM-21 and that the Clearly Defined Hed its actual day-to-day risk mitigation efforts.  Were any preferred stocks or bonds owned as of December 31 of the cur issuer, convertible into equity?	edule DB?	Yes [ Yes [ Yes [ Yes [ Yes [ Yes [		No [ X N/A ] oNo [ No [ No [ No [ X N	X ] ] ] ]	
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction  If yes, has a comprehensive description of the hedging program been may of the nature of the hedging program been may of the nature of the hedging program been may of the nature of the hedging program been may of the nature of the hedging entity utilizes.  Nature of Restriction  Nature of Restriction  If yes, has a comprehensive description of the hedging program been may of the hedging entity utilize of the reporting entity utilizes.  Nature of Restriction  Nature of Restricti	edule DB?	Yes [  Ye		No [ X N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ X/A ]	X ] ] ] ] ] ]0	
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction	edule DB?	Yes [  Ye		No [ X N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ N/A [ X/A ]	X ] ] ] ] ] ]0	
27.1 27.2 LINES 2 27.3 27.4 27.5	Does the reporting entity have any hedging transactions reported on Schol If yes, has a comprehensive description of the hedging program been malf no, attach a description with this statement.  27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY Does the reporting entity utilize derivatives to hedge variable annuity gual If the response to 27.3 is YES, does the reporting entity utilize:  27.41 Speci 27.42 Perm 27.43 Other  By responding YES to 27.41 regarding utilizing the special accounting profollowing:  • The reporting entity has obtained explicit approval from the domi • Hedging strategy subject to the special accounting provisions is • Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within the Financial Officer Certification has been obtained which indicates Hedging Strategy within VM-21 and that the Clearly Defined Hedits actual day-to-day risk mitigation efforts.  Were any preferred stocks or bonds owned as of December 31 of the curissuer, convertible into equity?  If yes, state the amount thereof at December 31 of the current year.  Excluding items in Schedule E - Part 3 - Special Deposits, real estate, morffices, vaults or safety deposit boxes, were all stocks, bonds and other socustodial agreement with a qualified bank or trust company in accordance Outsourcing of Critical Functions, Custodial or Safekeeping Agreements  I For agreements that comply with the requirements of the NAIC Financial	Description  edule DB?	Yes [  Ye		No [ X N/A ] oN N/A ] oN N/A [ N/A ] oN N/A [ X N/A ] on N/A ]	X ] ] ] ] ] ]0	

## **GENERAL INTERROGATORIES**

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:					
	. 1	2	3		

Name(s)	Location(s)		Complete Explanation(s)	
Have there been any changes, including name If yes, give full and complete information relatin	changes, in the custodian(s) identified in 2		ar? Yes [	] No [ X
1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason	

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2	
Name of Firm or Individual	Affiliation	
BLACKROCK FINANCIAL MANAGEMENT, INC	U	
Humana Inc.	1	

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. Yes [ X ] No [ ] designated with a "U") manage more than 10% of the reporting entity's invested assets?. 29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [ X ] No [ ]

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
107105	BLACKROCK FINANCIAL MANAGEMENT, INC	549300LVXY1VJKE13M84	The SEC	DS

Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Yes [ ] No [ X ] Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? If yes, complete the following schedule:

Book/Adjusted CUSIP# Name of Mutual Fund Carrying Value 30.2999 - Total

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

## **GENERAL INTERROGATORIES**

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	1,793,409,852	1,665,621,887	(127,787,965)
31.2 Preferred stocks	0	0	0
31.3 Totals	1,793,409,852	1,665,621,887	(127,787,965)

31.4	Describe the sources or methods utilized in determining the fair values:			
	Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of inactively traded debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates using either a market or income valuation.			
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [	]	No [ X ]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [	]	No [ ]
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:			
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes [ ]	( ]	No [ ]
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:  a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.  b. Issuer or obligor is current on all contracted interest and principal payments.			
	c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.	V [	,	N- [ V 1
	Has the reporting entity self-designated 5GI securities?	res [	1	No [X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:  a. The security was purchased prior to January 1, 2018.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.			
	d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.  Has the reporting entity self-designated PLGI securities?	1 aaV	1	No [ X ]
	Thas the reporting entity sen-designated it LOI securities:	162 [	1	NO [ X ]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:  a. The shares were purchased prior to January 1, 2019.  b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  The security hold a public and it stimp(a) with appendix an application and appendix appendix and appendix and appendix appendix and appendix appendix appendix and appendix appen			
	c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.			
	<ul> <li>d. The fund only or predominantly holds bonds in its portfolio.</li> <li>e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.</li> <li>f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not legal.</li> </ul>			
	f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.  Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	l seV	1	No [X]
		100 [	,	no [ x ]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:  a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.  b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.			
	<ul> <li>c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.</li> <li>d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a -</li> </ul>			
	37.c are reported as long-term investments.  Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1 No f	ī	N/A [ Y
	rias die reporting endry folieurenewed short-term of cash equivalent investifients in accordance with these criteria?	] INU [	1	IVA LA

38.1	Does the reporting entity directly hold cryptocurrencies?	Yes [	] No [ X ]
38.2	If the response to 38.1 is yes, on what schedule are they reported?		
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?	Yes [	] No [ X ]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?  39.21 Held directly		] No [ ] ] No [ ]
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.		
	1 2 3  Immediately Accepted f Converted to USD, Payment o Name of Cryptocurrency Directly Held, or Both Premium:	of	
	OTHER		
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?  List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations and statistical or rating bureaus during the period covered by this statement.		0
	1 2 Name Amount Paid		
41.1	Amount of payments for legal expenses, if any?	\$	49,415
41.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.		
	1 2 Name Amount Paid		
	SEYFARTH SHAW LLP		
42.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any?	\$	0
42.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.		
	1 2 Amount Paid		

## **GENERAL INTERROGATORIES**

## PART 2 - HEALTH INTERROGATORIES

1.1 1.2 1.3	Does the reporting entity have any direct Medicare Supplement Insurance in force If yes, indicate premium earned on U.S. business only		\$			0
1.3	1.31 Reason for excluding		. Φ			
						_
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien					0
1.5 1.6	Indicate total incurred claims on all Medicare Supplement Insurance	Most current three years:	. \$			
1.0	individual policies.	1.61 Total premium earned	\$			0
		1.62 Total incurred claims				
		1.63 Number of covered lives				
		All years prior to most current three years:				
		1.64 Total premium earned				
		1.65 Total incurred claims				
		1.66 Number of covered lives				0
1.7	Group policies:	Most current three years:				
		1.71 Total premium earned				
		1.72 Total incurred claims				
		1.73 Number of covered lives				0
		All years prior to most current three years:				_
		1.74 Total premium earned 1.75 Total incurred claims				
		1.75 Total incurred claims	-			
		1.76 Number of covered lives				0
2.	Health Test:	_				
		1 2 Current Year Prior Year				
	2.1 Premium Numerator					
	2.2 Premium Denominator					
	2.3 Premium Ratio (2.1/2.2)					
	2.4 Reserve Numerator					
	2.5 Reserve Denominator					
	2.6 Reserve Ratio (2.4/2.5)					
3.2	If yes, give particulars:					
4.1	Have copies of all agreements stating the period and nature of hospitals', physic dependents been filed with the appropriate regulatory agency?		Yes [ )	X]No	o [	]
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	se agreements include additional benefits offered?	Yes [	] No	о [ Х ]	]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [	] No	о [ Х ]	]
5.2	If no, explain: Stop-Loss Reinsurance is not required					
						_
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical				
		5.32 Medical Only5.33 Medicare Supplement				
		5.34 Dental & Vision				
		5.35 Other Limited Benefit Plan				
		5.36 Other				
6.	Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements agreements:  Provider contracts include hold harmless and continuation of benefits provisions	with providers to continue rendering services, and any other  s. Insurer has an indemnity agreement with the parent				
7.1	Does the reporting entity set up its claim liability for provider services on a service		' ا جولا	Y 1 N/	1 0	1
		e date basis!	103 [ 7	n ] INC	, i .	1
7.2	If no, give details					
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year .				
9.1	Does the reporting entity have business subject to premium rate guarantees?		Yes [ )	X ] No	) c	]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months	s \$		47,	505
		9.22 Business with rate guarantees over 36 months				

## **GENERAL INTERROGATORIES**

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in it	s provider contracts?	Yes [ X	] No	[ ]
10.2	If yes:	10.21 Maximum amount payable bonuses	\$	88 ,:	316,039
		10.22 Amount actually paid for year bonuses	\$	77 ,:	359,754
		10.23 Maximum amount payable withholds	\$		0
		10.24 Amount actually paid for year withholds	\$		0
11.1	Is the reporting entity organized as:				
		11.12 A Medical Group/Staff Model,	Yes [	] No	[ X ]
		11.13 An Individual Practice Association (IPA), or,	Yes [	] No	[ X ]
		11.14 A Mixed Model (combination of above)?	Yes [	] No	[ X ]
11.2	Is the reporting entity subject to Statutory Minimum Capital and Surplus Requiremen	its?	Yes [ X	] No	[ ]
11.3	If yes, show the name of the state requiring such minimum capital and surplus			Was	hington
11.4	If yes, show the amount required.		\$	966,	857 , 175
11.5	Is this amount included as part of a contingency reserve in stockholder's equity?		Yes [	] No	[ X ]
11.6	If the amount is calculated, show the calculation				
	See state regulation.				

12. List service areas in which reporting entity is licensed to operate:

1
Name of Service Area
AL - Medicare - Autauga, Baldwin, Bibb, Cherokee, Clarke, Colbert,
Cullman, Elmore, Escambia, Etowah, Fayette, Jackson, Jefferson,
Lauderdale, Lawrence, Limestone, Madison, Marshall, Mobile, Monroe,
Montgomery, Morgan, Pike, Shelby, Tuscaloosa, Walker, Washington
AK - Medicare - Anchorage, Fairbanks, North Star, Ketchikan Gateway,
Juneau, Matanuska-Susitna
AZ - Medicare - Coconino, Mohave, Yavapai
AR - Medicare - Arkansas, Baxter, Benton, Boone, Carroll, Clark,
Cleburne, Conway, Craighead, Crawford, Crittenden, Faulkner, Franklin,
Fulton, Garland, Grant, Greene, Hempstead, Hot Spring, Howard, Independence, Izard, Jefferson, Johnson, Lawrence, Little River, Logan,
Lonoke, Madison, Marion, Miller, Nevada, Newton, Ouachita, Perry, Pike,
Poinsett, Polk, Pope, Prairie, Pulaski, Randolph, Saline, Scott, Searcy,
Sebastian, Sevier, Sharp, Union, Van Buren, Washington, White
CA - Medicare - Alameda, Apline, Butte, Calaveras, Contra Costa, Fresno
Imperial, Kern, Kings, Lake, Los Angeles, Madera, Marin, Mendocino,
Merced, Monterey, Mono, Orange, Placer, Riverside, Sacramento, San
Bernardino, San Diego, San Francisco, San Joaquin, San Luis Obispo, San
Mateo, Santa Barbara, Santa Clara, Santa Cruz, Shasta, Sierra, Solano,
Sonoma, Stanislaus, Tehama, Tulare, Tuolumne, Ventura, Yolo
ID - Medicare - Ada, Bonner, Canyon, Kootenai, Payette
IN - Medicare - Statewide
KY - Medicare - Statewide
ME - Medicare - Statewide
MO - Medicare - Barry, Cedar, Christian, Dade, Dallas, Douglas, Greene,
Jasper, Laclede, Lawrence, McDonald, Newton, Polk, Pulaski, Stone,
Taney, Webster, Wright
NE - Medicare - Cass, Dakota, Dodge, Douglas, Lancaster, Sarpy,
Saunders, Washington
NH - Medicare - Belknap, Carroll, Hillsborough, Merrimack, Rockingham,
Strafford
OK - Medicare - Le Flore, Sequoyah
SC - Medicare - Allendale, Anderson, Berkeley, Charleston, Cherokee,
Colleton, Dorchester, Greenville, Pickens, Richland, Spartanburg, York.
TX - Medicare - Statewide
VA - Medicare - Botetourt, Chesapeake City, Franklin, Norfolk City,
Portsmouth City, Roanoke, Roanoke City, Salem City, Virginia Beach City,
Albemarle, Alexandria City, Arlington, Charlottesville City, Chesterfield, Colonial Heights City, Craig, Dinwiddie, Falls Church City
Fauquier, Floyd, Goochland, Hampton City, Hanover, Henrico, Hopewell
City, Isle of Wight, James City, Loudoun, Louisa, Manassas City,
Manassas Park City, Montgomery, Newport News City, Petersburg City,
Poquoson City, Powhatan, Prince William, Pulaski, Radford City, Richmond
City, Suffolk City, Williamsburg City, Wythe, York, Accomack, Alleghany,
Amelia, Amherst, Appomattox, Augusta, Bath, Bedford, Bedford City,
Bland, Brunswick, Buckingham, Buena Vista City, Campbell, Caroline,
Carroll, Charles City, Charlotte, Clarke, Covington City, Culpeper,
Cumberland, Danville City, Emporia City, Essex, Fairfax, Fairfax City,
Frederick, Fredericksburg City, Galax City, Giles, Gloucester, Greene,
Greenville, Halifax, Harrisonburg City, Henry, King and Queen, King
George, King William, Lancaster, Lexington City, Lunenburg, Lynchburg City, Madison, Martinsville City, Mathews, Mecklenburg, Middlesex,
Nelson, New Kent, Northampton, Northumberland, Nottoway, Orange, Page,
Patrick, Pittsylvania, Prince Edward, Prince George, Rappahannock,
Richmond, Rockbridge, Rockingham, Shenandoah, Southampton,
Spotsylvania, Stafford, Staunton City, Surry, Sussex, Warren, Waynesboro
City, Westmoreland, Winchester City, Highland, Franklin City, Fluvanna

Name of Service Area	
WV - Medicare - Boone, Cabell, Kanawha, Lincoln, McDowell, Mercer,	
Monroe, Putnam, Barbour, Berkeley, Braxton, Brooke, Calhoun, Clay,	
Doddridge, Fayette, Gilmer, Grant, Greenbrier, Hampshire, Hancock, Haro	dy
Harrison, Jackson, Jefferson, Lewis, Logan, Marion, Marshall, Mason,	
Mineral, Mingo, Monongalia, Morgan, Nicholas, Ohio, Pendleton,	
Pleasants, Pocahontas, Preston, Raleigh, Randolph, Ritchie, Roane,	
Summers, Taylor, Tucker, Tyler, Upshur, Wayne, Webster, Wetzel, Wirt,	
Wood, Wyoming	
WY - Medicare - Albany, Crook, Goshen, Laramie, Lincoln, Park, Platte,	,
Teton, Uinta, Weston	

13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$	0
13.3	Do you act as an administrator for health savings ac	counts?					Yes [ ]	No [ X ]
13.4	If yes, please provide the balance of funds administration	ered as of the rep	porting date				\$	0
14.1 14.2	Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [	] No [	] N/A [ X ]
	1	2	3	4		Supporting Reserv	e Credit	
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other	
15.	Provide the following for individual ordinary life insurceded):	rance* policies (l	J.S. business only)	15.1 [ 15.2 ]	Direct Premium Wr Fotal Incurred Clain	ittenns	\$	0
		*Ordir	nary Life Insurance	Includes				
	Term(whether full und				app")			
	Whole Life (whether			g, jet issue, "short	form app")			
	Variable Life (with or							
	Universal Life (with o Variable Universal Life			antee)				
16.	Is the reporting entity licensed or chartered, register	ed, qualified, elig	jible or writing busi	ness in at least tw	o states?		Yes [ X ] N	0 [ ]
16.1	If no, does the reporting entity assume reinsurance domicile of the reporting entity?						Yes [ ] N	o [ ]

## **FIVE-YEAR HISTORICAL DATA**


		1 2023	2 2022	3 2021	4 2020	5 2019
	Balance Sheet (Pages 2 and 3)	2020	2022	2021	2020	2019
1.	Total admitted assets (Page 2, Line 28)	2 158 835 707	1 848 763 682	1 751 171 135	1 506 487 750	1 246 852 720
	Total liabilities (Page 3, Line 24)					
2.	Statutory minimum capital and surplus requirement					
3.	Total capital and surplus (Page 3, Line 33)					
4.		1,080,181,054	930,291,835	912,923,407	879,045,229	/10,700,430
_	Income Statement (Page 4)	7 704 057 404	0 000 440 555	0.000.144.004	E E40 004 00E	4 045 007 500
5.	Total revenues (Line 8)					
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)	138,846,614	212,332,671	140,538,837	140,113,520	134,476,909
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	247,935,718	385,029,927	135,960,515	242,554,123	283,368,857
	Risk-Based Capital Analysis					
14.	Total adjusted capital					
15.	Authorized control level risk-based capital	179,562,917	167,940,796	163,296,531	137,325,207	108,214,412
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7) .	510,816	471,461	491,705	445,510	385 , 108
17.	Total members months (Column 6, Line 7)	6,034,366	5,700,931	5,796,995	5,179,311	4,461,256
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x $100.0$					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	84.7	84.6	85.9	83.0	84.5
20.	Cost containment expenses	4.8	2.9	2.8	2.6	2.8
21.	Other claims adjustment expenses	0.4	0.4	0.4	0.5	0.5
22.	Total underwriting deductions (Line 23)	98.5	96.7	97.7	97.0	96.8
23.	Total underwriting gain (loss) (Line 24)	1.5	3.3	2.3	3.0	3.2
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	489,564,832	513,934,907	482,245,079	363,574,992	222,912,075
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	562,835,240	551, 155,799	561,854,363	361,247,174	235 , 169 , 737
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)					
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated				0	
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to					
55.	31 above.	0	0 tated due to a merger in	0	0	(

## SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories


Allocated by States and Territories  1 Direct Business Only												
			1	2	3	4	5	6	7	8	9	10
								Federal Employees	Life and			
			Active	Assidant and				Health Benefits	Annuity	Proporty/	Total	
			Status	Accident and Health	Medicare	Medicaid	CHIP Title	Program	Premiums & Other	Property/ Casualty	Total Columns 2	Deposit-Type
	States, etc.		(a)	Premiums	Title XVIII	Title XIX	XXI	Premiums	Considerations	Premiums	Through 8	Contracts
1.	Alabama	AL	L	0	778,826,105	0	0	0	0	0	778,826,105	0
2.	Alaska	AK	L	0	0	0	0	0	0	0	0	0
3. 4.	Arkansas	AZ AR	L	0	0	0	0	0	0	0		
5.	California	CA	L	0	1,696,950,105	0	0	0	0	0	1,696,950,105	0
6.	Colorado	CO	N	0	0	0	0	0	0	0	0	0
7.	Connecticut	CT	N	0	0	0	0	0	0	0	0	0
8.	Delaware	DE	N	0	0	0	0	0	0	0	0	0
9.	District of Columbia	DC	N	0	0	0	0	0	0	0	0	0
	Florida	FL	N	0	0	0	0	0	0	0	0	0
11.	Georgia	GA	N	0	0	0	0	0	0	0	0	0
	Hawaii	HI	N	0	0	0	0	0	0	0	0	0
13. 14.	IdahoIllinois	ID IL	L N	0	0	0	0	0	0	0	12,780,337	
15.	Indiana	IN	IV	0	1.441.836.363	0	0	0	0	0	1.441.836.363	
16.	lowa	IA	N	0	0	0	0	0	0	0	0	0
17.	Kansas	KS	N	0	0	0	0	0	0	0	0	0
18.	Kentucky	KY	L	0	530,628,286	0	0	0	0	0	530,628,286	0
19.	•	LA	N	0	0	0	0	0	0	0	0	0
20.	Maine	ME	L	0	111,626,488	0	0	0	0	0	111,626,488	0
21.	Maryland	MD	N	0	0	0	0	0	0	0	0	0
22.	Massachusetts	MA	N	0	0	0	0	0	0	0	0	0
23.	Michigan	MI	N	0	0	0	0	0	0	0	0	0
24. 25		MN	N	0	0	0	0	0	0	0	0	0
25. 26.	Mississippi Missouri	MS MO	N	0	0	0	0	0	0	0	0	0
26. 27.	Montana	MT	N	0	0	0	0	0	0	0	0	n
28.	Nebraska	NE	I	0	(1, 165)	0	0	0	0	0	(1.165)	n
29.		NV	N	0	0	0	0	0	0	0	0	0
30.	New Hampshire	NH	L	0	37, 436, 673	0	0	0	0	0	37, 436, 673	0
31.	•	NJ	N	0	0	0	0	0	0	0	0	0
32.	New Mexico	NM	N	0	0	0	0	0	0	0	0	0
33.	New York	NY	N	0	0	0	0	0	0	0	0	0
34.		NC	N	0	0	0	0	0	0	0	0	0
35.	North Dakota	ND	N	0	0	0	0	0	0	0	0	0
36.	Ohio	OH	N	0	0	0	0	J0	0	0	0	0
37.	Oklahoma	OK	L N	0	14,039,326	0	0 0	0	0	0	14,039,326	0
38. 39.	OregonPennsylvania	OR PA	N N	0	0	0	0	0	0	0	0	0
39. 40.	Rhode Island	PA RI	N	0	0	n	٥	n	n	0	0	n
41.	South Carolina		L	0	1,120,864,276	0	0	0	0	0	1,120,864,276	0
42.	South Dakota	SD	N	0	0	0	0	0	0	0	0	0
43.	Tennessee	TN	N	0	0	0	0	0	0	0	0	0
44.		TX	L	0	(1,070)	0	0	0	0	0	(1,070)	0
	Utah	UT	N	0	0	0	0	0	0	0	0	0
		VT	N	0	0	0	0	0	0	0	0	0
	-	VA		0	494,426,947		0	0	0	0	494,426,947	0
48.	-	WA		0	727,280,677	0	0	0	0	0	727,280,677	0
	=	WV	L	0	165,601,174	0	0	0	0	0	165,601,174	0
	Wisconsin Wyoming	WI WY	N L	0	0	0	0 0	0	0	0	0	0
51. 52.	American Samoa			0	0		0 0	0	0	0	0	0
52. 53.	Guam	GU	N	0	0	0	0	0	0	0	0	0
54.		PR	N	0	0	0	0	0	0	0	0	0
	U.S. Virgin Islands		N	0	0	0	0	0	0	0	0	0
	Northern Mariana											
	Islands	MP	N	0	0		0	0	0	0	0	0
57.		CAN	N	0	0	0	0	0	0	0	0	0
58.	Aggregate Other Aliens	ОТ	XXX	0	0	0	0	0	0	0	0	0
59.	Subtotal		XXX		7,734,857,401		0		0		7,734,857,401	0
60.	Reporting Entity				, , , , , , , , ,						, , , ,	
	Contributions for En			_		_	-	_	_	_	_	_
64	Benefit Plans		XXX	0	0		0	0	0	0	7 724 957 401	0
61.	Totals (Direct Busine DETAILS OF WRITE	-	XXX	0	7,734,857,401	0	U	0	U	Ü	7,734,857,401	0
58001.	DETAILS OF WRITE		XXX	0	0	0	Λ	0	n	n	0	0
58002.			XXX									
58003.			XXX									
58998.	Summary of remaining											
	write-ins for Line 58 f		XXX	0	0	0	٥	0	0	0	0	0
58999	overflow page Totals (Lines 58001 t				U		0	J	U	U	J	
	58003 plus 58998)(Li											
( · \ * ··	above) e Status Counts:		XXX	0	0	0	0	0	0	0	0	0
a \ A ctive												

<sup>(</sup>b) Explanation of basis of allocation by states, premiums by state, etc. The Company reports premium based on the situs of the contract




40.1


**Echo Primary Care Holdings Organization Chart** 





## Prime West Organizational Chart


As of 12/31/2023















































## **OVERFLOW PAGE FOR WRITE-INS**

# NONE